Child	Deficiency of the limb	Associated anomaly	Relation of the relative	Limb anomaly of the relative

1	split hand of right upper limb	none	sibling	(not reported)

2	split hand of right upper limb	none	sibling	(not reported)

3	split hand of right upper limb	none	sibling	(not reported)

4	split hand of right upper limb	none	sibling	(not reported)

5	split hand of both upper limbs and split foot of both lower limbs	none	sibling	(not reported)

6	radial deficiency of left upper limb	Fanconi’s anemia	sibling	(not reported)

7	ulnar deficiency of right upper limb	none	sibling	(not reported)

8	transverse deficiency at the level of hand of right upper limb	none	sibling	(not reported)

9	split hand of right upper limb	none	mother	anomalies of radius and ulna

10	split hand of right upper limb	none	father	split hand

11	split hand of both upper limbs	none	father	split hand

12	split hand of left upper limb and tibial deficiency of both lower limbs	none	granduncle	split hand

13	split foot of right lower limb	none	someone other than sibling	(not reported)

14	ulnar deficiency of both upper limbs and split foot of both lower limbs	Leri-Weill syndrome	mother	Madelung deformity, and Leri-Weill syndrome

15	ulnar deficiency of both upper limbs and tibial deficiency of both lower limbs	none	mother and grandmother	upper limb anomaly

16	transverse deficiency at the level of hand of right upper limb	none	relative on the mother’s side	toe defect

17	transverse deficiency at the level of foot of both lower limbs	none	father and grandfather on the father’s side	anomaly of fifth finger


Genus (family)	Order/suborder	Organelle genome	Inheritance	Reference

Equisetum (Equisetaceae)	Equisetales	Plastome	Maternal	Guillon and Raquin, 2000

Ceratopteris (Pteridaceae)	Polypodiales/Pteridineae	Plastome	Maternal	Adjie et al., 2007

Pellaea (Pteridaceae)	Polypodiales/Pteridineae	Plastome and mitogenome	Maternal	Gastony and Yatskievych, 1992

Asplenium (Aspleniaceae)	Polypodiales/Aspleniineae	Plastome	Maternal	Vogel et al., 1997

Deparia (Athyriaceae)	Polypodiales/Aspleniineae	Plastome and mitogenome	Maternal	This study


Date	Event

28 to 31 Oct 2008	Fifteenth Session of the IBC (2 days); Joint Session of the IBC and IGBC (2 days) (Paris)

9 to 10 Jul 2009	Sixth Session of the IGBC (Paris)

23 to 25 Nov 2009	Sixteenth Session of the IBC (Mexico City)

26 to 29 Oct 2010	Seventeenth Session of the IBC (2 days)*,; Joint Session of the IBC and IGBC (2 days)* (Paris)

31 May to 2 Jun 2011	Eighteenth Session of the IBC* (Baku)

5 to 6 Sep 2011	Seventh Session of the IGBC* (Paris)


Whole group, n = 92

Age (median) 59.5 years

Gender:	Male	32 (35 %)

	Female	60 (65 %)

Treatment intent:	Palliative	7	Radical	85

N-stage	T-stage	No. of patients	% of total

 N0	T1	19	20.7

 N0	T2	37	40.2

 N0	T3	20	21.7

 N0	T4	6	6.5

 N1	T3	1	1.1

 N1	T4	4	4.4

 N2	T3	3	3.3

 N3	T3	1	1.1

 N3	T4	1	1.1

Radical treatment

Chemoradiotherapy plus boost, n = 52

Anal canal		Anal margin

Iridium boost, n = 36		Electron boost, n = 16

Age (median) 61 years		Age (median) 63 years

Stage	No. of patients (%)	Stage	No. of patients (%)

 T1 N0	3 (8.3)	T1 N0	4 (25)

 T2 N0	17 (47.2)	T2 N0	7 (43.8)

 T3 N0	14 (38.9)	T3 N0	2 (12.5)

 T2 N2	1 (2.8)	 –	–

 T3 N2	1 (2.8)	 –	–

–	–	T4 N0	2 (12.5)

–	–	T4 N1	1 (6.2)

Radical treatment (other)

External beam radiotherapy alone	8

Chemoradiotherapy without boost	25


	Cell line	EC50 of MTX

MCF-7	human breast adenocarcinoma	2.58 × 10−8M

MDA-MB 231	human breast adenocarcinoma	5.06 × 10−7M

T-24	human bladder carcinoma	8.07 × 10−8M

PANC-1	human pancreatic carcinoma	2.34 × 10−8M

HT29	human colon adenocarcinoma	6.09 × 10−8M

A375	human melanoma	3.37 × 10−8M

HT-1376	human bladder carcinoma	1.71 × 10−7M

OVCAR-3	human ovarian carcinoma	8.95 × 10−8M


Strain name	Genotype	Reference

yMD7	MATaade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100 bar1::Hyg	This study

	pep4::KanMX

	MCM6::MCM6-3 × FLAG (Nat-NT2)

yMD8	MATaade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100 bar1::Hyg	This study

	pep4::KanMX

	MCM6::MCM6-3 × FLAG (Nat-NT2)

	his3::HIS3pRS303/CDT1,GAL4

	trp1::TRP1pRS304/MCM4, MCM5 leu2::LEU2pRS305/MCM6TC, MCM7 ura3::URA3pRS306/MCM2, CBP-MCM3

yMD9	MATaade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100,	This study

	cdc7-4, pep4:: Hyg,

	MCM10::MCM10-3 × FLAG (Nat-NT2)

	his3::HIS3pRS303/SLD3-13MYC,

	trp1::TRP1pRS304/SLD2, leu2::LEU2pRS305/SLD7, CDC45,

	ura3::URA3pRS306/DPB11

yMD16	MATa/α ade2-1/ade2-1 ura3-1/ura3-1 his3-11,15/his3-11,15 trp1-1/trp1-1 leu2-3,112/leu2-3,112 can1-100/can1-100 MCM10+/mcm10Δ472-571 (Nat-NT2)	This study

yMD17	MATa/α ade2-1/ade2-1 ura3-1/ura3-1 his3-11,15/his3-11,15 trp1-1/trp1-1 leu2-3,112/leu2-3,112 can1-100/can1-100 MCM10+/mcm10Δ472-571 (Nat-NT2) RAD9/rad9Δ::KanMX	This study


	KEGG ID	KEGG term	HypergeometricP-value	CorrectedP-value (BF)

	hsa05200	Pathways in cancer	6.16E−08	1.23E−05

	hsa04110	Cell cycle	7.96E−08	1.58E−05

	hsa04144	Endocytosis	1.34E−07	2.67E−05

Down	hsa04520	Adherens junction	2.55E−07	5.08E−05

	hsa04310	Wnt signaling pathway	1.16E−06	2.31E−04

	hsa05220	Chronic myeloid leukemia	4.39E−06	8.73E−04

	hsa04114	Oocyte meiosis	4.90E−06	9.75E−04

	hsa05200	Pathways in cancer	2.47E−09	5.14E−07

	hsa05220	Chronic myeloid leukemia	4.54E−08	9.45E−06

	hsa04144	Endocytosis	3.80E−07	7.91E−05

	hsa05215	Prostate cancer	7.45E−07	1.55E−04

Up	hsa04110	Cell cycle	7.71E−07	1.60E−04

	hsa04115	p53 signaling pathway	2.31E−06	4.80E−04

	hsa04120	Ubiquitin mediated proteolysis	2.33E−06	4.84E−04

	hsa05210	Colorectal cancer	2.51E−06	5.22E−04

	hsa04520	Adherens junction	2.82E−06	5.87E−04


plasma DBP (μg/mL)	GAgP group (n = 59)	Control group (n = 58)

r 	P value	r 	P value

Mean BI	0.1588	0.251	0.048	0.768

Mean PD	−0.1347	0.327	−0.190	0.216

Mean AL	−0.164	0.230	None	—

Severe sites %	−0.167	0.233	None	—


NCC material	After 48 h	After 336 h	After 336 h + freezing and thawing

Untreated	−	−	+

10 kGy	+	+	+

20 kGy	+/− 1	+	+

30 kGy	−	+/− 1	+

40 kGy	−	+/− 1	+

50 kGy	−	−	+

60 kGy	−	−	−


Group	Mean calluses width, mm ± SD	Mean calluses length, mm ± SD	Regeneration zones ± SD	Embryogenesis appearance, %

Control	4.18 ± 1.36	6.22 ± 0.67	1.24 ± 0.48	20

AgNPs	5.37 ± 3.47	7.00 ± 2.54	2.01 ± 0.98	34

AuNPs	6.39 ± 2.82	6.55 ± 2.36	3.29 ± 1.07	49


Surgery	Ratio between post-discharge SSIs and in-hospital SSIs

Vascular surgery	0

Breast surgery	3,4

Cesarean section	2,5

Cholecistectomy	1,2

Gastric surgery	0,4

Appendectomy	0,2

Colon surgery	0,1

Hernia repair	1,4

Abdominal hysterectomy	0,6

Vaginal hysterectomy	1


Outcome Measures	Importance	Validity	Scientific soundness	Usability	Feasibility	Ranking

CGI-SCH	HIGH	HIGH	MED	MED	HIGH	1

Degree of involvement in vocational rehabilitation	HIGH	HIGH	MED	MED	HIGH

Brief Psychiatric Rating Scale	MED	HIGH	MED	MED	MED

Degree of Independent Living	HIGH	HIGH	MED	LOW	MED

PANSS	MED	MED	MED	MED	LOW

Service user Satisfaction Survey Responses	HIGH	LOW	LOW	MED	MED

Development of Metabolic Syndrome/Diabetes	HIGH	HIGH	MED	MED	MED

GAF Score	MED	MED	MED	MED	MED

Process Adherence Measures

 Percentage of Service users on Multiple Antipsychotics (excluding clozapine)	MED	HIGH	MED	HIGH	MED	1

 Percentage of service users who have metabolic monitoring at recommended intervals	HIGH	HIGH	HIGH	HIGH	LOW	2

 Percentage of service users referred for supported employment/vocational services	HIGH	MED	HIGH	HIGH	HIGH	3

 Percentage of service users referred to CBT for psychosis	HIGH	MED	HIGH	HIGH	HIGH	4

 Percentage of service users on recommended dosages (within therapeutic range) of antipsychotic medication	MED	MED	MED	HIGH	LOW

 Percentage of service users with a summary of previous medication trials	MED	MED	MED	HIGH	MED

 Percentage of first-episode service users who have had a MRI brain	MED	LOW	LOW	HIGH	HIGH

 Percentage of service users that have an annual physical exam	MED	LOW	LOW	HIGH	HIGH


Ingenuity Canonical Pathwaya	C2b	C3	C4

Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F	3.47E-08

Communication between Innate and Adaptive Immune Cells	6.17E-08

TREM1 Signaling	1.1E-07

Differential Regulation of Cytokine Production in Macrophages and T Helper Cells by IL-17A and IL-17F	2.09E-07

Role of Cytokines in Mediating Communication between Immune Cells	0.000331

MSP-RON Signaling Pathway	0.000331

Dendritic Cell Maturation	0.000427

Acute Phase Response Signaling	0.002399

Crosstalk between Dendritic Cells and Natural Killer Cells	0.002455

IL-17A Signaling in Fibroblasts	0.002754

Chemokine Signaling	0.012303

Glucocorticoid Receptor Signaling	0.016218

NF-kB Signaling	0.016982

LXR/RXR Activation	0.032359

p38 MAPK Signaling	0.033884

IL-6 Signaling	0.038019

IL-12 Signaling and Production in Macrophages	0.038905

G-Protein Coupled Receptor Signaling		0.006166

Role of PI3K/AKT Signaling in the Pathogenesis of Influenza		0.019055

Crosstalk between Dendritic Cells and Natural Killer Cells		0.039811

Activation of IRF by Cytosolic Pattern Recognition Receptors			1.58E-11

Interferon Signaling			1.23E-10

Role of RIG1-like Receptors in Antiviral Innate Immunity			2.24E-05

Retinoic acid Mediated Apoptosis Signaling			0.000148

Role of PKR in Interferon Induction and Antiviral Response			0.000832

Role of JAK1, JAK2 and TYK2 in Interferon Signaling			0.002884

Role of MAPK Signaling in the Pathogenesis of Influenza			0.032359

IL-10 Signaling	0.012303	0.00537

Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses	3.31E-05		3.24E-08

Role of IL-17F in Allergic Inflammatory Airway Diseases	0.000257		0.010965

Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza	0.000132	0.000891	0.006918


Characteristic	Burkina Faso*	Senegal*	Niger*	Ghana*

Surveillance design	Prospective	Retrospective	Retrospective	Prospective

Geographic extent	Three districts	Dakar	Niamey	Northern area

Surveillance population	880,000	950,000	550,000	140,000

Rural/Urban	Both	Urban	Urban	Rural

Study years	2002-2005	1970-1979	1981-1996	1998-2003

Microbiological methods	Culture, antigen detection, PCR	Culture	Culture, antigen detection	Culture, antigen detection

Number of confirmed pneumococcal meningitis cases	249	983	934	76

Percent of cases occurring during dry/epidemic season months of Dec-Apr†	75%	49%	63%	69%

Two months with peak number of cases (percent of total)†	Jan-Feb (38%)	Feb-Mar (21%)	Feb-Mar (31%)	Dec-Jan (35%)

Relation of pneumococcal to meningococcal seasonal peak	Similar	2 months in advance	1 month in advance	1 to 2 months in advance

13-valent conjugate vaccine coverage of isolated serotypes

Age <5 years	67%	78% (age<2 yrs)	No serotype data	100%

Age 5+ years	77%	94% (age 2+ yrs)	No serotype data	98%

Reference	4,5	9	8	7


Algal species	Protein	Carbohydrates	Lipids

Anabaena cylindrica[96]	43–56	25–30	4–7

Aphanizomenon flos-aquae[96]	62	23	3

Chlamydomonas reinhardtii[96]	48	17	21

Chlorella minutissima[21]	9–24	14–42	31–57

Auxenochlorella protothecoides[97]	11–26	17–24	25–54

Auxenochlorella protothecoides[21]	36–38	41–52	11–23

Chlorella pyrenoidosa[96]	57	26	2

Chlorella emersonii[21]	28–32	11–41	29–63

Chlorella sorokiniana[21]	42–45	32–38	20–22

Chlorella vulgaris[96]	51–58	12–17	14–22

Chlorella vulgaris[21]	7–29	51–55	18–40

Dunaliella salina[96]	57	32	6

Euglena gracilis[96]	39–61	14–18	14–20

Nannochloropsis sp.[98]	23–59	5–17	9–62

Porphyridium cruentum[96]	28–39	40–57	9–14

Scenedesmus obliquus[96]	50–56	10–17	12–14

Spirogyra sp.[96]	6–20	33–64	11–21

Arthrospira maxima[96]	60–71	13–16	6–7

Spirulina platensis[96]	46–63	8–14	4–9

Synechococcus sp.[96]	63	15	11


Factors	Post-progression survival

Hazard ratio	95% CI	p-value

Age (years) at the beginning of first-line treatment	0.98	0.94–1.02	0.47

Chemoradiotherapy (sequential/concurrent)	2.25	0.66–7.04	0.18

Best response at second-line treatment (NonPD/PD)	0.22	0.10–0.47	< 0.01

Distant metastases at recurrence (yes/no)	2.42	1.18–5.22	0.01

Administration of platinum-based agents after first-line treatment (yes/no)	0.92	0.41–1.98	0.83

Number of regimens after first-line treatment	0.75	0.56–0.98	0.04


Route	N	(%)

Internet	2511	(42.0)

TV or Movie	3185	(53.2)

Retail Store	2138	(35.7)

Billboard	810	(13.6)

Vehicle	483	(8.1)

Event	686	(11.5)

Magazine or newspaper	2062	(34.9)


Cohort 3	Patients with ∆ reticulin and/or collagena (N = 7)	Patients with no ∆ collagen or reticulin (N = 51)

Age, median (Q1, Q3), years	47 (30, 60)	44 (33, 61)

ITP duration, median (Q1, Q3), years	4.1 (1.2, 9.1)	2.2 (1.2, 7.1)

Prior splenectomy rate, n (%)	2 (29)	17 (33)

Platelet responseb, median (Q1, Q3)	Time to first platelet response, weeks	15 (7, 21)c	3 (2, 8)d

Weeks with platelet response, %	5 (0, 28)	38 (28, 76)

Exposuree, median (Q1, Q3)	Average weekly dose, μg/kg	9 (7, 9)	2 (1, 5)

Maximum weekly dose, μg/kg	10 (9, 10)	4 (3, 10)

Cumulative dose, μg/kg	1207 (204, 1358)	345 (136, 610)


Pollen recipient (♀)	Pollen donor (♂)	Number of flowers	Number of fruits	Fruit set (%)	Mean number of seeds per fruit	Seed viability (%)	Mean number of viable seeds per fruita

B. crispa	B. crispa	20	11	55	65.50	34	22.27

	B. officinalis	24	14	58	8.00	68	5.44

	Putative hybrid	27	15	55	2.20	70	1.54

B. officinalis	B. crispa	32	2	6	1.00	0	0.00

	B. officinalis	23	10	43	65.00	91	59.15

	Putative hybrid	37	18	48	1.94	57	1.11

Putative hybrid	B. crispa	31	19	61	2.79	0	0.00

	B. officinalis	38	32	84	4.63	53	2.45

	Putative hybrid	45	7	15	0.43	0	0.00


	Stroke/TIA Patients	Control Subjects	Significance

Age, yr	53.9±9.3	53.8±9.0	ns.

Males, n (%)	21 (52.5)	21 (52.5)	ns.

Body mass index, kg/m2	28.7±4.8	25.3±4.1	0.002

Body surface area, m2	2.0±0.2	1.8±0.2	0.033

Caucasian race, n (%)	40 (100.0)	40 (100.0)	ns.

Hypertension, n (%)	16 (40.0)	0 (0.0)	<0.001

Hyperlipidemia, n (%)	14 (35.0)	16 (40.0)	ns.

Diabetes, n (%)	0 (0.0)	0 (0.0)	ns.

Left ventricle ejection fraction, %	66.0±10.2	63.7±7.7	ns.

Left ventricle dysfunction, n (%)	0 (0.0)	0 (0.0)	ns.

Smokers, n (%)	0 (0.0)	1 (2.5)	ns.


Characteristics	n = 10

Age	63.8±12.0

Body Mass Index	27.1±3.7

Parity	2 (1-3)

Health problems	6

SUI	2

Previous hysterectomy	5

Previous POP surgery	10

POP	10

Point C/D POPQ median (range)	3 (2-4)

Central compartment prolapse stage ≥ 3	10

Cystocele stage ≥ 2	9

Rectocele stage ≥ 2	7

Enterocele stage ≥ 2	0

Concomitant procedure	6

Anterior colporrhaphy	4

Posterior colporrhaphy	2

MUS	0


 	Infection-associated EHPM (+)	Infection-associated EHPM (−)	Odds ratio (95% CI)	P value

HCV Ab (+)	27	240	3.15 (1.19–8.37)	0.0194

HCV Ab (−)	5	140

HBs Ag (+)	4	61	11.31 (2.03–63.11)	0.0067

HBs Ag (−)	2	345

No viral infection	4	67	20.30 (2.23–184.46)	0.0036

Any viral infection 	1	340


miRNAs	Known functional effect	Targets	References

mir-15a, miR-15b, miR-16, and miR-195	Pancreas development, beta-cells fate and regeneration	Neurog3	[33]

miR-375	Beta- and alpha-cells expansion	 	[42]

miR-7a	Beta-cell proliferation	mTOR pathway components	[44, 45, 48]

miR-124a	Pancreas development	Foxa2	[33]


Patient/source	Our patient	Patients TB/LB from Joyce et al. [13]	Patient DP from Monk et al. [17]	Patients HC/AC from Monk et al. [16]	Patient from Eggermann et al. [6] (decipher 285981)	Decipher 289205	Decipher 276327	ISCA nssv579045

Genomic location (hg19)	chr7:50654827-5122921	chr7:42029531–51138357(D7S691-D7S242)	chr7:40742989–50861159 (D7S1769-GRB10)	chr7:41392336–54000000 (RP5-953B5-7p11.2)	chr7:47034222–52175639	chr7:50713413-50982532	chr7:43566637-51282735	chr7:33367924-61831899

Duplication size	574Kb	~10 cM	~10 cM	>10 cM	5.1 Mb	270Kb	7.72 Mb	28.5 Mb

Inheritance/orign	de novo/maternal	LB: maternal	de novo/maternal	AC: maternal	de novo/paternal	inherited/paternal	de novo/unknown	unknown

TB: paternal	HC: unknown

Phenotype	SRS	SRS	SRS	SRS-like	overgrowth, DD, microcephaly, seizure	hypotonia, GDD	muscular hypotonia	FTT, GDD, large eyes, microcephaly, short stature, triangular face

Detection method	array	karyotype/FISH	karyotype/FISH	karyotype/FISH	array	array	array	array

Genes involved (Refseq)	GRB10 and part of COBL	>50 genes	>50 genes	>50 genes	>20 genes	Part of GRB10	>40 genes	>180 genes


Group	Treatment (mg/kg) once daily orally		Study 1	Study 2

A	None (placebo, control)	Cohort 1	4 f	2 m & 2 f

Cohort 2	4 m	2 m & 2 f

B	Benazepril (0.5–1.0)	Cohort 1	4 f	2 m & 2 f

Cohort 2	4 m	2 m & 2 f

C	Robenacoxib (1.0–2.4)	Cohort 1	4 f	2 m & 2 f

Cohort 2	4 m	2 m & 2 f

D	Benazepril (0.5–1.0) + Robenacoxib (1.0–2.4)	Cohort 1	4 f	2 m & 2 f

Cohort 2	4 m	2 m & 2 f


Extract of questionnaire

Frequency of muscle pain that was reported in clinical trials on statins:

	Statins	Placebo	p-value

 Cochrane 2013 N = 37,938, primary prevention	9.5 %	9.2 %	0.40

 Finegold 2014 N = 46,262, primary prevention	7.9 %	7.6 %	0.407

 Finegold 2014 N = 37,618, secondary prevention	4.8 %	4.6 %	0.558

Question: If 100 patients take this statin – in how many of them does the intake of this statin cause muscle pain?a

 Responses (No)	0	1	>1	>10	No response

 Format multiple choice

 Group 6 (n = 87) Pharmacy group	10 (12 %)	12 (14 %)	48 (55 %)	14 (16 %)	3 (3 %)


Themes	Subthemes	Representative statements

Cultural and linguistic barriers 	Major barriers in terms of language and culture result in older adults' dependency on others when it comes to medical visits	“The biggest problem is the language barrier. We feel helpless since we do not speak English, and we cannot resolve matters without English. Even if you understand English you would not comprehend their technical terms.” “The people I contact are few. I don't want to bother my children.”

Immediate family support may not always be available to assist older adults with medical visits	“If you need your son to bring you to the doctor's clinic, he would have no time because he has to work. If you cannot find someone else, then you just have to wait until he comes home.” “To ride the bus you need to know how to get there... you need to draw it on a piece of paper with the directions. I was to take bus no. 4, and it would transfer three times. But still I did not make it (to the hospital). I was lucky to return home from the final bus stop.”

Affordability of services 	The health care system is poorly understood. The utilization and degree of satisfaction differ depending on older adults' insurance coverage and length of residence	“As new comers, we have nothing. My mother-in-law is old, and, moreover, I am old too, I am sixty eight years old. As we age, the most critical thing is medical treatment and benefits. Getting your white card, it would not be a big deal even if you are sick. We depend on the medical supply by mail. It is tough to see a doctor. Besides it is far away. And not knowing English, it is difficult to visit a doctor. The medical expenses are high.” “It's like we have to pay for everything. We have nothing and yet we need to pay for the medication expenses.”

For those who are fully insured, they feel fortunate compared to that of their counterparts in China	“Buying insurance is now only getting started in China. Previously, I bought insurance. Now I apply for low-income status. So I do not have to buy insurance and it is so much better. America is definitely taking that route. You have no money. The government helps out with a low income status. If you apply, it will not cost you any money.” “I think the most pleasant thing for me in the US is what happened to my two legs. My legs were broken twice in the US if that happened in China, my children and I would not be able to afford the surgeries. Here in the US, I do not have to pay a single cent. They even provided me the walking equipment and the toilet pans. I think this is the best thing happened to me. I feel very happy and thankful for that.”

Availability of services 	The long wait and inflexibility of health care services often frustrated participants	“I think the waiting period to see a doctor is too long. It takes several hours and you are not seeing your doctor right away. Definitely it is too long.” “I think there is something that America is not comparable to China. That is the appointment system. They are not letting you see the doctor today, unless you are going to the emergency room! They will not let you see the doctor right away; it would take a week. Then you need to go to the emergency room. I think that situation is not good.”

The expectation toward medical visits is often compared to older participants' experience in China where quick improvement is anticipated	“In Shanghai, if I do not feel good, I can go to see the doctor right away. Over here, this appointment thing, you would need two weeks to see your family physician. He has his vacations and you need to wait two weeks. But hey, I am sick... I have this illness and I need to see the doc right away. I think over here, you need to go to the hospital, the UIC Hospital. It is because of the insurance that requires you to visit the hospital. Today you can visit this hospital and tomorrow you can visit that hospital. And that is OK.” “Like suffering from nerve pain... if you are in China, you just visit the clinic to get a pain killer shot. Over here the waiting period is not fast. I went there and took several hours. Going to the hospital for minor ailments is not convenient.”.


Performance parameter	Melody type

	Simple	Complex

8th note onset	0.57	0.49

16th note onset	0.38	0.54

Micro-timing onset	0.14	−0.12

8th note offset	0.48	0.09

16th note offset	0.23	0.26

Micro-timing offset	−0.09	−0.02

8th note duration	−0.37	−0.35

16th note duration	−0.17	−0.23

Micro-timing duration	−0.05	−0.08

Density	0.51	0.38

R2 (variance explained)	0.562	0.532


Construct name	Primer combination

NbPDS (2046 bp)	NbPDSfor1 × NbPDSrev1

NbPDS (1661 bp)	NbPDSfor2 × NbPDSrev1

NbPDS (1304 bp)	NbPDSfor3 × NbPDSrev1

NbPDS (959 bp)	NbPDSfor4 × NbPDSrev1

NbPDS (610 bp)	NbPDSfor5 × NbPDSrev1

NbPDS (257 bp)	NbPDSfor6 × NbPDSrev1

NbPDS (345 bp)	NbPDSfor3 × NbPDSrev2

NbPDS (192 bp)	NbPDSfor7 × NbPDSrev3

NbPDS (103 bp)	NbPDSfor7 × NbPDSrev4

NbPDS (54 bp)	NbPDSfor8 × NbPDSrev5

NbPDS (385 bp)	NbPDSfor1 × NbPDSrev6

NbPDS (357 bp)	NbPDSfor2 × NbPDSrev7

NbPDS (349 bp)	NbPDSfor4 × NbPDSrev8

NbPDS (353 bp)	NbPDSfor5 × NbPDSrev9

NbPDS (2046 bp + polyA)	NbPDSfor1 × NbPDSrev6

NbPDS (1661 bp + polyA)	NbPDSfor2 × NbPDSrev6

NbPDS (1304 bp + polyA)	NbPDSfor3 × NbPDSrev6

NbPDS (959 bp + polyA)	NbPDSfor4 × NbPDSrev6

NbPDS (610 bp + polyA)	NbPDSfor5 × NbPDSrev6

NbPDS (257 bp + polyA)	NbPDSfor6 × NbPDSrev6

NbPDS (345 bp + polyA)	NbPDSfor7 × NbPDSrev7

NbPDS (345 bp + polyG)	NbPDSfor7 × NbPDSrev8


CAT item	Comorbidity	p value	Cumulative R2

Cough

 	None

Phlegm

 	None

Chest tightness

 	GERD (FSSG ≥ 8)	<0.001	0.0901

 	Depression (HAD-D ≥ 11)	0.0033	0.123

Breathlessness

 	GERD (FSSG ≥ 8)	<0.001	0.0705

 	Osteoporosis	0.0355	0.0876

Activity limitation

 	GERD (FSSG ≥ 8)	<0.001	0.0926

 	Depression (HAD-D ≥ 11)	<0.001	0.1452

 	Arrhythmia	0.0026	0.1773

 	Osteoporosis	0.0222	0.1954

Confidence to leave home

 	GERD (FSSG ≥ 8)	<0.001	0.0631

 	Depression (HAD-D ≥ 11)	<0.001	0.107

 	Osteoporosis	<0.001	0.1337

 	Hypertension	0.0109	0.1571

 	Arrhythmia	0.0445	0.1714

Sleep

 	Depression (HAD-D ≥ 11)	<0.001	0.0807

 	GERD (FSSG ≥ 8)	0.0033	0.1134

 	Anxiety (HAD-A ≥ 11)	0.01	0.1378

 	Arrhythmia	0.0404	0.153

Energy

 	GERD (FSSG ≥ 8)	<0.001	0.1191

 	Depression (HAD-D ≥ 11)	<0.001	0.1972

 	Arrhythmia	<0.001	0.2487

 	Anxiety (HAD-A ≥ 11)	0.0333	0.263


Variables	N (%)

Experienced an occupational injury	13 (32.5)

Knows other workers who have been injured	21 (52.5)

Major types of injury (N = 13)

Broken bone	3 (23.1)

Inhalation	3 (23.1)

Accidental injection/needle stab	3 (23.1)

Muscle sprain or strain	3 (23.1)

Part of body injured

Leg, knee, or hip	4 (30.8)

Hand or wrist	3 (23.1)

Eyes	2 (15.4)

Head or neck	1 (7.7)

Back	1 (7.7)

Arms or shoulders	1 (7.7)

Fingers	1 (7.7)

Cause of injury

Animal	10 (76.9)

Machine	2 (15.4)

Other	1 (7.7)

Lost time due to injury

No time lost	8 (61.5)

2-6 days lost	1 (7.7)

More than 30 days lost	4 (30.8)

Have health problems due to working with hogs	11 (28.2)

Type of occupational health problems

Allergies	3 (7.5)

Asthma	2 (5.0)

Bronchitis	2 (5.0)

Coughing	7 (17.5)

Eyes burning	10 (25.0)

Headaches	7 (17.5)

Hearing problems	2 (5.0)

Infections	1 (2.5)

Muscular pain	9 (22.5)

Nausea	4 (10.0)

Nasal congestion	4 (10.0)

Sneezing	6 (15.0)

Skin disorders	1 (2.5)

Pain in throat	3 (7.5)


Disease	Trimester	Aminotransferases	Bilirubin	INR	Treatment	Prognosis*

Hyperemesis gravidarum	First	Up to 2-3 times upper limit of normal	<4	Always normal	Supportive	Excellent

Intrahepatic cholestasis of pregnancy	Second/third	Elevated sometimes rarely >1000	Elevated but <6	Typically normal	Ursodeoxycholic acid	Good

AFLP	Third	Elevated usually <1000	Elevated	Usually elevated	Delivery	Guarded

HELLP	Third	Elevated, variable, 5-20 times upper limit of normal	>1.2	Sometimes elevated	IV magnesium, BP control, delivery	Guarded

Acetaminophen	Any	>50 times upper limit of normal	Elevated usually <10	Usually elevated	NAC	Good if NAC administered promptly

Ischemia	Any	>50 times upper limit of normal	Elevated usually <4	Usually elevated (<3)	Supportive	Variable, depends on underlying disease

Viral	Any	>25 times upper limit of normal	Elevated	Variable	Supportive	Variable

Drug-induced	Any	>25 times upper limit of normal	Elevated	Variable	Supportive	Variable

Autoimmune	Any	5-10 times upper limit of normal	Normal	Variable	Corticosteroids, azathioprine	Variable


Scenario	Skin Area	Months	Time

S1	35% (face, hands, forearms, lower legs)	March–September	Constant

S2	35% (face, hands, forearms, lower legs)	June–August	Constant

10% (face and hands)	March–May, September

S3	10% (face and hands)	March–September	Constant

S4	35% (face, hands, forearms, lower legs)	June–August	Varies with latitude (equivalent to 1 SED) *


Affective words	Answer	Categories of associated words

		Synonyms	Antonym	Life event	Relative behavior	Others

Happiness	Number	36	2	42	7	3

	Frequency (%)	40.45	2.24	47.19	7.87	3.37

Sadness	Number	21	0	47	17	4

	Frequency (%)	23.60	0	52.81	19.10	4.49

Anger	Number	25	1	45	10	8

	Frequency (%)	28.09	1.12	50.56	11.24	8.99

Fear	Number	29	0	52	6	1

	Frequency (%)	32.58	0	58.43	6.74	1.12


country	summarized area characteristics	number of species	references

Africa	continent-wide estimate (insects only)	600	DeFoliart (1992)

Africa	sub-Saharan Africa (insects only)	250	van Huis (2003)

Africa	Central and West Africa (plants only)	1500	Chege (1994)

Botswana	Tyua grow crops and use wild plants, animals, birds, fish and insects	171	Hitchcock (1999)

Congo	Mbuti Pygmies of forest: cultivators of cassava and plantain plus users of 230 animal and 100 plant species	330	Ishikawa (1999)

Ethiopia	subsistence agriculture, animal husbandry, semi-arid to humid	44	Fentahun & Hager (2009)

Ethiopia	country-wide estimate	203	Asfaw & Tadesse (2001)

Ethiopia	country-wide estimate	300	Asfaw (2009)

Ethiopia	agricultural, arid, open woodland (50% of plants in region edible)	25	Becker (1983)

Ethiopia	humid to semi-arid; forest to savannah, three ethnic groups in south Ethiopia	66	Balemie & Kebebew (2006)

Kenya	country-wide estimate for agricultural communities (plants only)	800	Maundu (1996)

Kenya	Turkana agro-pastoralists and rural fishing communities, arid and semi-arid	14	Levine & Crosskey (2006)

Madagascar	forest-dwelling, swidden cultivation in tropical forest	150	Styger et al. (1999)

Namibia	agriculture and livestock; tropical wetland, swamp and woodland in Caprivi	21	Mulonga (2003)

Nigeria	agricultural, savanna, semi-arid	121	Harris & Mohammed (2003)

Tanzania	agricultural, tropical forest, East Usambara mountains	28	Kessey (1998)

Tanzania	agricultural, tropical forest, East Usambara mountains	46	Hårkönen & Vainio-Mattila (1998)

Tanzania	Batemi agropastoralists, semi-arid (with 35 wild species cultivated)	44	Johns et al. (1996)

Uganda	agricultural households in southwest Uganda (some wild species cultivated and gathered from the wild)	94	Musinguzi et al. (2006)

Zambia	country-wide estimate	15–25	Pegler & Piearce (1980)


Summary of clinical data of the study group consisting of colon cancer patients, pre-malignant adenoma patients and healthy control patients

Parameter	Value	Colon cancer (CC) patients	Healthy control (H) patients	Adenoma (A) patients	P-value

 	 	(n = 164)	(n = 119)*	(n = 34)

Sex	Female	68 (41.5%)	67 (56.3%)	16 (47.1%)	0.738

 	Male	96 (58.5%)	52 (43.7%)	18 (52.9%)

Age	Range	40.5 – 99.1	19.5 – 90.8	28.1 – 86.1	0.144 (A vs H)

(years)	Mean	69.59	62.41	63.65	0.004 (CC vs H)


Gene	Primer	Sequence	Annealing temperature/elongation time	Literature

16S, rrnA	pF1	AGAGTTTGATCCTGGCTCAG	55°C/60 sec	[32]

 	pR4	CCAGCAGCCGCGGTAATAC	 	[33]

sodA	sodA-F	TRCAYCATGAYAARCACCAT	50°C/60 sec	[34]

 	sodA-R	ARRTARTAMGCRTGYTCCCARACRTC	 	[34]

groEL	StreptogroELd	GAHGTNGTIGAAGGIATGCA	52°C/60 sec	[35]

 	StreptogroELr	ATTTGRCGIAYWGGYTCTTC	 	[35]

gdh	GDHsoralisF	ATGGACAAACCAGCTAGCTT	55°C/60 sec	[6]

 	GDHsoralisR	GCTTGTGGTCCCATGCTTCC	 	[6]

gtfR	gtfRSoralisF	TCCCGGTCAGCAAACTCCAGCC	52°C/60 sec	[36]

 	gtfRSoralisR	GCAACCTTTGGATTTGCAAC	 	[36]

cshA-like	CshA-F	AAGTACAAGGTGCAGATG	46°C/40 sec	This study

 	CshA-R	CATTTGCAGTAGCTATCG	 	This study

rib-like	RibF	GTGACYTACCCAGATGG	47°C/30 sec	This study

 	RibR1	CAATWGAATCTTCWGCC	 	This study

pitA-like	pitAF	ATTWSTCCAATTCAGGGGC	55°C/45 sec	This study

 	pitAR	AATGCCCGCGTCCATACC	 	This study

integrase	InGraF	CTCATGATGTCAAAGAG	46°C/40 sec	This study

 	InGraR	GATTTGGAAYCGTGTGG	 	This study

hylA-like	hylAF	CAGCAAAGGGATGCCAAG	60°C /60 sec	This study

 	hylAR	CCTTCCAGTTCCTGGTTTAAC	 	This study

Tigurinus 16S, rRNA	TIGFCTT	AGAACGCTGAAGCTTGGT	55°C /30 sec	This study

 	TIGFAGA	GTAGAACGCTGAAGAGAGG	 	This study

 	TIGR	ATTATCATGCGATAATCAATT	 	This study

Mitis-group sodA	sodA-MSF	GCMAAYGCAGCTCTTGAA	58°C /35 sec	This study

 	sodA-MSR	ACCAACCAHGCCCATCCA	 	This study


GR Operation	Operation Zone	Total Population	Total Populated Households	Total Households	Total Structures

GR1:Outer Islands, Temotu Province	Duff Islands	556	118	158	399

	Reef Islands	5958	1179	1468	3746

	Utupua	1300	259	330	770

	Vanikolo	1602	308	399	938

	GR1: Total	9416	1864	2355	5853

GR2: Santa Cruz, Temotu Province	Santa Cruz East	3950	717	881	1873

	Santa Cruz West	8162	1563	1970	4046

	GR2: Total	12112	2280	2851	5919

GR3: Tanna IRS Zone, Tafea Province	Health Zone 1	5363	1064	1283	5214

	Health Zone 2	9395	1863	2196	7299

	Health Zone 3	3096	653	773	2923

	Health Zone 4	4115	866	1001	3455

	GR3: Total	21969	4446	5253	18891


Gene		Sequence	Product size	Annealling temperature

MMP-2	Sense	5'-GGATGATGCCTTTGCTCG-3'	487 bp	55°C

	Anti-sense	5'-ATAGGATGTGCCCTGGAA-3'

MMP-7	Sense	5'-CTTCAGGCAGAACATCCA-3'	220 bp	49°C

	Anti-sense	5'-ATTTATTGACATCTACCCAC-3'

MMP-9	Sense	5'-AGGACGGCAATGCTGATC-3'	127 bp	58°C

	Anti-sense	5'-TCGTAGTTGGCGGTGGTG-3'

MT1-MMP	Sense	5'-CCTGCGTCCATCAACACT-3'	481 bp	57°C

	Anti-sense	5'-TCACCTCCGTCTCCTCCTC-3'

SFRP5	Sense	5'-AGGGTAAGGGAAAGGTGGAG-3'	379 bp	60°C

	Anti-sense	5'-GAGAAGCAGAGGCTGAGGAA-3'

GAPDH	Sense	5'-GGGAAACTGTGGCGTGAT-3'	309 bp	56°C

	Anti-sense	5'-AAAGGTGGAGGAGTGGGT-3'


Year	First author	Type of study	Number and type of patients considered	Patients with solitary splenic metastases from NPC	Patient’s age, sex (M, F)	Comorbidity	Primary treatment for NPC	Disease-free survival after primary treatment	Methods of detection of splenic metastasis	Treatment for solitary splenic metastasis	Confirmatory histology of NPC splenic metastases	Overall survival (status at last follow-up)	Relapse after splenic surgery

2000	Lam & Tang [3]	CS	92 patients with splenic metastases	1 (1.1 %)	M	NS	NS	NS	NS	- Splenectomy	UCNT	NS	NS

2013	Suh et al. [38]	CR	1 non-keratinizing NPC	1	35 years old, M	EBV	- Neoadjuvant chemotherapy (cysplatin and 5-fluorouracil)- Left medial maxillectomy with left modified radical neck dissection- Adjuvant radiochemotherapy (cysplatin and 63 Gy)	7 months	FDG-PET/CT FNA biopsy	- Systemic chemotherapy (docetaxel and cysplatin)- Laparoscopic splenectomy	UCNT	5 months (alive)	Nil

2015	Abu-Zaid et al. [27]	CR	1 NPC	1	26 years old, M	NS	- Surgical resection- Adjuvant radiochemotherpay	6 years	CTFNA biopsy	- Splenectomy	UCNT	12 months (alive)	Nil

2015	Present study	CR	1 NPC	1	56 years old, M	Smoker, EBV	- Neoadjuvant chemotherapy (docetaxel, carboplatin, and 5-Fluorouracil)- Radiotherapy (70 Gy)	3 months	PET/CT	- Laparoscopic splenectomy	UCNT	4 months (alive)	Nil


Health Effects	US	EU	Canada	Australia	New Zealand

Mortality:			1,042		1,296,552 (premature death) [198]

VSL: Adults	6,300,000	2,247,191	3,480,000	1,439,394	1,717,241 (1,724,138) [198]

VSL: Children	2 × adult	4088764 (infant)

VSLY		134,831		70,455	118,621

Morbidity:				1929.55 (average cost/separation) [199]

Morbidity: children	2 × adults

Chronic bronchitis	340,000	213,483

Chronic asthma	39,000

Respiratory hospital admission	14,000	2,247	1,032		2,069

CVD hospital admission	21,000	2,247	1,052		2,759

Emergency room visit	300 (asthma)		541 (respiratory) 562 (CVD)

Doctor's visit		60

RAD	106	92 (working age) 78 (young, elderly)	22		53

MRAD	50	43

Acute respiratory symptom	3–24

Use of respiratory medication		1.12

Asthma day	32–74	43	15

References:	[54]	[127]	[200]	[128]*	[129]


Register	Data available	Register holder	Ref.

Medical Birth Register	Mother’s health data (incl. Smoking habits prior to and during pregnancy, other risk factors, interventions), pregnancy, delivery, live and stillbirths, GD, BMI, infant health data by age of 7 days	THL	[30]

Register of Induced Abortions	Data on mother, indication for induced abortion, diagnoses	THL	[38]

Register of Congenital Malformations	Mother’s health data, pregnancy, foetus/child, congenital anomalies and birth defects, diagnoses (ICD codes)	THL	[31]

Care Register for Health Care	Data from hospitals and special health care, diagnoses	THL	[33]

Register of Primary Health Care Visits	Data outpatient health care visits, diagnoses (available since 2011)	THL	[34]

Cancer Register	Persons with cancer, data on cancer type and death certificate	THL	[32]

Cause-of-Death Register	Causes of death, death certificates	Statistics Finland	[36]

Register of reimbursements for Prescription Medicines	Purchases of prescription medication eligible for reimbursement	KELAa	[35]

Finnish Maternity Cohort	Serum bank, data on mother, sampling date, expected due date, previous pregnancies	THLb	[42]

Population Register	Address history	Population Register Center	[37]


		Frequency in patients: Percent (%)in four categories of severity

Severity of complaints	Population % Standard	<underline>Before</underline> therapy %	<underline>After</underline> therapy %

Total score

No or little (-4)	48	26.4	86.8

Mild (5–8)	25	18.2	8.4

Moderate (9–15)	20	27.8	4.0

Severe (16+)	8	27.6	0.8

Psychological score

No or little (-1)	48	30.7	82.5

Mild (2–3)	23	17.0	10.4

Moderate (4–6)	20	22.2	5.5

Severe (7+)	9	30.1	1.6

Somatic score

No or little (-2)	53	35.7	93.0

Mild (3–4)	24	22.7	5.1

Moderate (5–7)	15	25.5	1.6

Severe (8+)	8	16.1	0.3

Sexual score

No or little (0)	64	37.3	76.8

Mild (1)	13	13.3	11.6

Moderate (2–3)	16	22.2	8.7

Severe (4+)	7	27.3	2.9


Attributes	SED Group	SEA Group	Unadjusted

	Na	%	Na	%	OR (95% CI)

SOCIODEMOGRAPHIC

Marital Status	213		424

 Has partner		79		99	0.05 (0.02–0.13)

Education	212		432

 Less than high school		25		5	2.25 (1.93–2.63)

Cultural Identity	211		428

 Canadian		50		61	0.61 (0.44–0.85)

Language Spoken at Home	217		431

 English		63		82	0.37 (0.26–0.49)

Country of Birth	215		421

 Canada		45		70	0.35 (0.25–0.49)

WOMAN'S HEALTH

Overall Health	215		431

 Very good/Excellent		41		59	0.48 (0.35–0.67)

Symptoms of Postpartum Depression	211		426

 EPDS ≥ 12		19		8	2.7 (1.64–4.4)

Hospital Readmission	216		431

 YES		3		2	1.57 (0.57–4.28)

PHYSICIAN

Has Family Doctor	215		430

 YES		96		97	0.74 (0.3–1.84)


Image	Diameter Measurement Method	Error (%) Relative to MD in Image LS

Min	Average	Max

LS	MAL-F2	0.1	1.2	3.8

MD	0.5	5.8	16

IS	MAL-F1	0.8	5.6	12.2

MAL-F2	0.2	15.0	60.5


Characteristic	Entire cohort	By distance (m) to nearest A1–A3 roadway (m)b

≥ 200	51–199	0–50

Age (years)c	42.0 ± 5.1	42.1 ± 5.1	41.9 ± 5.2	42.0 ± 5.3

BMI (kg/m2)	25.9 ± 6.0	25.8 ± 5.9	26.0 ± 6.1	26.4 ± 6.4

Census tract median income ($10,000)	6.68 ± 2.38	6.75 ± 2.29	6.66 ± 2.47	6.33 ± 2.56

Census tract median home value ($100,000)	1.72 ± 1.24	1.67 ± 1.08	1.84 ± 1.41	1.76 ± 1.57

Caucasian race	94	94	93	93

Age at menarche (years)

< 12	23	23	23	23

12	30	30	30	31

> 12	46	47	46	46

Parity

Nulliparous	18	16	21	25

Parous	82	84	79	75

Oral contraception use

Never	14	13	16	15

Past	75	75	73	74

Current	10	10	10	10

Cigarette smoking

Never	67	68	66	65

Current	9	8	10	10

Former	24	24	24	24

Infertility

Yes	4	4	4	4

No	94	94	94	94

Ever performed rotating shift work

Yes	69	69	69	70

No	31	31	31	30

Region

Northeast	34	32	37	42

Midwest	34	35	31	30

West	15	14	20	15

South	17	19	13	13

Values are mean ± SD or percent. aValues are standardized to the age distribution of the study population. bEach cohort member may be in multiple distance categories over follow-up. cValues are not age-adjusted


	Team response1	Individual response

	Number of teams analysed	Number of questionnaires send	Number of questionnaires returned	Number of questionnaires analysed

Internal medicine	11	142	127	115

Surgery	10	83	77	69

Radiology	7	45	42	42

Total	28	270	246	226


Query	SQL	SQL	SPARQL	SPARQL

	count	time	count	time

	result		result

Recovery all Patients	207.190	0,060s	207.190	0,189s

Recovery all Therapies	400.290	0,132s	400.290	0,317s

Recovery all Diagnosis	240.088	0,070s	240.088	0,220s

Recovery all Courses	108.297	0,030s	108.297	0,155s

Recovery patients with diagnosis, therapies and courses	207.190	1,048s	207.190	0,204s

Recovery all female Patients	105.714	0,231s	105.714	0,189s

Recovery all female Patients with more of 60 years old	62.603	0,245s	62.603	0,192s


Jeddah A	Val68Met+Asn126Asp+Ser188Phe

Jeddah B	Val68Met+Ser188Phe

Jeddah C	Asn126Asp+Ser188Phe

Jeddah D	Ile48Thr+Val68Met

Jeddah E	Ile48Thr+Ser188Phe


NHANES, FPED Dataset 1	USDA-ERS Dataset 2

Total meat	Total meat, fish, eggs and nuts

 Meat Cured Meat Poultry Organ meat Seafood from high omega-3 sources Seafood from low omega-3 sources	 Total red meat Total Poultry Total fresh and frozen, canned, and cured fish and shellfish Eggs Peanuts Total tree nuts Coconut

Meat	Total red meat

 Beef Veal Pork Lamb Game meat	 Beef Veal Pork Lamb

Cured Meat	Category not included in dataset

 Cured or luncheon meat made from beef, pork or poultry

Poultry	Total poultry

 Chicken Turkey Cornish hens Game birds	 Chicken Turkey

* Two categories of Seafood	Total fresh and frozen, canned, and cured fish and Shellfish

 Seafood from high omega-3 sourcesFinfishShellfishOther seafood Seafood from low omega-3 sourcesFinfishShellfishOther seafood	 Total fresh and frozen fish and shellfishFresh and frozen fishFresh and frozen shellfish Total canned fish and shellfishCanned salmonCanned sardinesCanned tunaCanned shellfishOther canned fish Cured Fish

Other Categories in the dataset	Other Categories in the dataset

 Organ Meat	 Eggs

Organ meat from beef, veal, pork, lamb, game or poultry 	 Peanuts

 Total Tree nutsAlmondsHazelnutsPecansWalnutsMacadamia nutsPistachio nutsOther tree nuts

	 Coconut


Departments	Internal Medicine (n = 19)	Urology (n = 19)	Total (n = 38)

Number of beds, mean (SD)	67 (22)	18 (9)	43 (30)

% Female physicians, mean (SD)	33 (13)	17 (15)	25 (16)

Teaching hospital department*	17 (89)	12 (63)	29 (76)

Residents working at the department	19 (100)	16 (84)	35 (92)

Microbiological laboratory in the same building as the department	12 (63)	8 (42)	20 (53)

Reporting of a positive urine culture by phone (incidentally or structurally)	0	2 (11)	2 (5)

Structurala education on antibiotics for residents	14 (74)	4 (21)	18 (47)

Structural education on antibiotics for senior staff members	4 (21)	0	4 (11)

Audit and feedback (incidentallyb or structurally)

On antibiotic prescriptionsc, at the department level	2 (11)	8 (42)	10 (26)

On antibiotic prescriptionsc, at the individual level	0	2 (11)	2 (5)

On antibiotic resistance rates of the hospital	9 (47)	12 (63)	21 (55)

Individual advice (of microbiologist/ pharmacist/ infectious diseases (ID) physician), incidentally or structurally, regarding streamlining therapy on the basis of blood or urine culture result	16 (84)	16 (84)	32 (84)

Microbiologist and/or ID physician structurally present at ward rounds discussing antibiotic therapy	6 (32)	0	6 (16)

Quality improvement project concerning antibiotic prescribing in past 3 years	8 (42)	7 (37)	15 (40)

Changes in antibiotic procedures or policies in past 3 yearsd	13 (68)	14 (74)	27 (71)


miRNA Name	Consensus Sequence	Fold Change

Up Regulated miRNAs	3 h	24 h

miR-129-5p	CUUUUUGCGGUCUGGGCUUGC	19.8	9.5

miR-200a-3p	UAACACUGUCUGGUAACGAUGU	15.9	8.8

miR-297	AUGUAUGUGUGCAUGUGCAUG	15.6	18.6

miR-200b-3p	UAAUACUGCCUGGUAAUGAUGA	14.7	10.2

miR-595	GAAGUGUGCCGUGGUGUGUCU	10.4	9.3

miR-574-5p	UGAGUGUGUGUGUGUGAGUGUGU	7.2	8.6

miR-647	GUGGCUGCACUCACUUCCUUC	4.1	5.0

miR-615-3p	UCCGAGCCUGGGUCUCCCUCUU	3.9	4.3

miR-1224-5p	GUGAGGACUCGGGAGGUGG	3.5	4.2

miR-1238-3p	CUUCCUCGUCUGUCUGCCCC	2.2	2.2

miR-196a-5p	UAGGUAGUUUCAUGUUGUUGGG	3.1	-

miR-616-3p	AGUCAUUGGAGGGUUUGAGCAG	3.9	-

miR-760	CGGCUCUGGGUCUGUGGGGA	3.7	-

miR-1275	GUGGGGGAGAGGCUGUC	2.1	-

miR-146a-5p	UGAGAACUGAAUUCCAUGGGUU	-	13.7

miR-631	AGACCUGGCCCAGACCUCAGC	-	12.6

miR-661	UGCCUGGGUCUCUGGCCUGCGCGU	-	7.7

miR-766-3p	ACUCCAGCCCCACAGCCUCAGC	-	4.6

miR-1273a	GGGCGACAAAGCAAGACUCUUUCUU	-	2.8

miR-1202	GUGCCAGCUGCAGUGGGGGAG	-	2.7

miR-943	CUGACUGUUGCCGUCCUCCAG	-	2.7

miR-1250-5p	ACGGUGCUGGAUGUGGCCUUU	-	2.6

miR-1229-3p	CUCUCACCACUGCCCUCCCACAG	-	2.5

Down Regulated miRNAs

miR-301b-3p	CAGUGCAAUGAUAUUGUCAAAGC	−3.3	−2.8

miR-548a-3p	CAAAACUGGCAAUUACUUUUGC	−3.1	−3.1

miR-377-3p	AUCACACAAAGGCAACUUUUGU	−2.1	−3.2

miR-602	GACACGGGCGACAGCUGCGGCCC	−2.1	-

miR-802	CAGUAACAAAGAUUCAUCCUUGU	−2.2	-

miR-376b-3p	AUCAUAGAGGAAAAUCCAUGUU	-	−2.9

miR-216b-5p	AAAUCUCUGCAGGCAAAUGUGA	-	−2.4

miR-216a-5p	UAAUCUCAGCUGGCAACUGUGA	-	−2.4

miR-410-3p	AAUAUAACACAGAUGGCCUGU	-	−2.3

miR-29b-3p	UAGCACCAUUUGAAAUCAGUGUU	-	−2.1


Sample	Number of seeds per score category (n)

	No germination and seed coat infection (Score = n × 0)	Seed coat and radical tip infection (Score = n × 1)	Either seed coat or radical tip infection (Score = n × 2)	Healthy seed germination (Score = n × 3)	Total score

Control (+)	None	None	None	6	18

Control (-)	5	1	None	None	1

10 mg l-1	2	3	1	None	5

25 mg l-1	1	2	2	1	9

50 mg l-1	None	None	2	4	16

100 mg l-1	None	None	1	5	17

200 mg l-1	None	None	None	6	18


Learner	General practice	Hospital	Other	All

Doctors	43 (49%)	3 (3%)	-	46 (52%)

Nurses	16 (18%)	20 (23%)	4 (5%)	40 (45%)

Students	-	-	2 (2%)	2 (2%)


AMP family	D. melanogaster gene	HMM state	Induction	Average Coverage (Naïve)	Average Coverage (Infected)

Attacins	AttA	strongly induced	21.59	1.33	38.37

	AttB	strongly induced	23.23	2.26	70.20

	AttC	strongly induced	35.90	0.96	46.29

	AttD	ND1

Cecropins	CecA1	strongly induced	27.33	1.18	43.20

	CecA2	strongly induced	43.80	0.68	39.59

	CecB	ND

	CecC	ND

Defensins	Def	moderately induced	3.35	7.68	34.40

Diptericins	Dpt	strongly induced	80.26	2.99	320.51

	DptB	strongly induced	Inf	0.00	30.37

Metchnikowin	Mtk	strongly induced	23.47	7.94	249.23

Drosocin	Dro	strongly induced	17.07	28.03	640.13

Drosomycins	Drs	strongly induced	6.99	19.28	180.39

	Dro2	ND

	Dro3	ND

	Dro4	not regulated	0.95	12.74	10.00

	Dro5	ND

	Dro6	ND

	Drs-l	ND


 	Artificial data	Biological data

Scenario characteristics	1st design	2nd design	1st design	2nd design

Total cost / expectation	97443.4	151629.7	210917.0	535524.0

Total cost / expectation of gains	60.0	358.4	53448.0	77040.5

Total cost / expectation of losses	38024.0	56660.0	98376.0	187600.5

Total cost / expectation of duplications	26796.0	34324.6	38286.0	44639.6

Total cost / expectation of transfers	32563.4	60168.3	17887.0	223854.8

Total cost / expectation of the gain_big events	0.0	118.4	2920.0	2388.6

Running time	<1m	2m	15m	41m


Characteristics	Number	Percent

Age group (years)

 14–24	44	18.0

 25–34	54	22.1

 35–44	124	50.8

 45 and above	22	9.0

 Total	244	100

Highest educational level

 Primary	14	5.7

 Junior High School	64	26.2

 Senior High School	54	22.1

 Tertiary	96	39.3

 Post-Graduate	14	5.7

 Uneducated	2	0.8

 Total	244	100

Tribe

 Akan	112	45.9

 Ewe	58	23.8

 Ga	44	18.0

 Northern	30	12.3

 Total	244	100

Parity

 Zero	156	63.9

 1 and above	88	36.1

 Total	244	100

Body Mass Index

 <25	76	31.1

 25–29.9	78	32.0

 30 and above	90	36.9

 Total	244	100

Menstrual flow pattern (heavy flow)

 Yes	102	41.8

 No	142	58.2

 Total	244	100

Type of menstrual cycle (irregular)

 Yes	164	67.2

 No	80	32.8

 Total	244	100


Instruments	Domains	Mean ± Standard Deviation

JSS	Payment–promotion	3.38 ± 0.65

Management–interpersonal relationship	4.33 ± 0.66

Organization–communication	4.41 ± 0.70

Total score	3.92 ± 0.55

TAS-20	Difficulty describing feelings	12.97 ± 5.48

Difficulty identifying feelings	13.90 ± 5.18

Externally oriented thinking	18.01 ± 4.27

	Total score	44.89 ± 11.56


Variable	Odds ratio	95 % confidence interval	p value

Moderate to high side effects (ref: no/low side effects)	4.84	1.07–1.85	0.04


	Six County Study Area	Entire State of Michigan

Current smoking	25.1%	25.1%

Heavy drinking (60+ drinks/mo)	2.6%	3.7%

Binge drinking (5+ drinks on 1+ occasions in past month)	7.6%	11.7%

Cholesterol never checked	16.1%	19.3%

Ever told cholesterol high (among tested)	37.4%	33.0%

Ever told high blood pressure	33.6%	31.4%

Overweight (BMI >= 27.8 for men, >= 27.3 for women)	34.6%	33.4%

Never had mammogram (among women 40+)	19.0%	22.2%


Stratification criteria

Variable	Criteria

Student mobility

IHE-Yes	Any respondent declaring at least one study-related trans-border movement

IHE-No	Any respondent declaring no study-related trans-border movement

IHE-North	Destination countries of international health electives (IHE) are pre-dominantly industrialised countries.(Eligible combinations: n, nn, snn, nns, nsn, nnn)*

IHE-South	Destination countries of international health electives (IHE) are pre-dominantly developing countries.(Eligible combinations: s, ss, sn, ns, ssn, sns, nss, sss)*

Exposure to educational interventions

GH-yes	Any respondent declaring a participation in global health courses.

GH-no	Any respondent declaring no participation in global health courses.

TM-yes	Any respondent declaring a participation in courses of tropical medicine.

TM-no	Any respondent declaring no participation in courses of tropical medicine.


	NP	Gestational day 20	Gestational day 50

Endometrium	Chorioallantoic membrane	Endometrium	Chorioallantoic membrane

H	A	H	A	H	A	H	A

PCR samples (No.)	5	30	19	26	20	29	6	27	4

WB samples (No.)	-	6	6	6	6	6	6	6	6

IF samples (No. of sections from different animals)	-	3	3	3	3	3	3	3	3


Scenario	Parameter	Settings

A1–A5	Signal to noise (s2n)	0.01, 0.05, 0.1, 0.15, and 0.20

B1–B5	Mean of significant variables in the case	10, 15, 20, 25, and 30

C1–C5	Dispersion parameter of significant variables in the case	0.125, 0.5, 1, 2, and 8

 	Sample size (+/−)	40 (20/20)

 	Number of variables	500

 	Mean of significant variables in the control	5

 	Mean of insignificant variables	5

 	Dispersion parameter of significant variables in the control	1

 	Dispersion parameter of insignificant variables	1


Variables	p value	OR	95% CI for OR

Lower	Upper

Variables associated with diarrhea in children aged more than 6 months

Starting of breastfeeding

 After an hour of birth	0.045	1.479	1.009	2.166

 Within hour (reference category)

Nutritional status of children	0.029

 Moderate malnutrition	0.758	0.909	0.497	1.666

 Overweight	0.209	0.695	0.394	1.227

 Severe malnutrition	0.018	1.853	1.111	3.089

 Normal (reference category)

Duration of breastfeeding

 Up to 2 years	0.026	2.506	1.114	5.638

 2 years or more (reference category)

Variables associated with cough and cold in children aged more than 6 months

Hand washing before each feed

 Always (reference category)

 Sometimes	0.039	0.620	0.394	0.977

Nutritional status of child	0.115

 Moderate malnutrition	0.590	1.221	0.590	2.527

 Overweight	0.636	1.182	0.591	2.363

 Severe malnutrition	0.015	2.135	1.159	3.933

 Normal (reference category)

Washing utensils after each feed

 After each feed (reference category)

 Sometimes	0.001	0.457	0.282	0.740

Occupation

 Employed	0.022	0.546	0.325	0.916

 Housewife (reference category)


Culture medium/additives	Manufacturer	Order no.	Concentration

Dulbecco’s modified Eagle medium (DMEM) with l-glutamine, plus 4.5 g glucose, without NaHCO3, without Natriumpyruvate	Life Technology, Carlsbad, USA	11966-025

Penicillin/streptomycin	Life Technology, Carlsbad, USA	15640-055	100 IU penicillin/100 μg streptomycin/ml

Ca2+/Mg2+ free Hanks’ balanced salt solution (HBSS)–buffer	Life Technology, Carlsbad, USA	14170-070

Fetal calf serum (FCS)	Life Technology, Carlsbad, USA	10270-098	10%

l-Glutamate	Life Technology, Carlsbad, USA	25030-024	1%

Ethylenediaminetetraacetic acid (EDTA) solution	Sigma Aldrich, St. Louis, USA	E7889	0.5 M

l-Ascorbic acid 2-phosphate	Sigma Aldrich, St. Louis, USA	A-8960	1 mmol/l ASC (affinity isolated antibody)

Dexamethasone	Serva Bioproducts, Heidelberg, Germany	18660	100 nmol/l


Fold enrichment (P value)	↑ in Dupl5q cortex	↓ in Dupl5q cortex	↑ In idiopathic ASD cortex	↓ In idiopathic ASD cortex

All genes	↑ 1500 in DPSC neurons	1.41(le-6)	1.06(0.5)	1.25(0.05)	1.14(0.3)

↓ 1500 in DPSC neurons	0.87(0.1)	0.95(0.6)	0.97(0.8)	1.07(0–6)

All genes except 15qll-13 genes	↑ 1500 in DPSC neurons	1.37(le-5)	1.07(0.4)	1.26(0.04)	1.09(0.5)

↓ 1500 in DPSC neurons	0.88(0.1)	0.95(0.6)	0.96(0.8)	1.08(0.5)


Cytological findings	Final histological diagnosis

SQC	SCLC	ADC	ADC/SQC	LC/LNC	Carcinoid	Other	Benign	Total

SQC	47	0	9	1	6	0	0	0	63

SCLC	0	3	1	0	3	0	0	0	7

ADC	1	0	107	1	3	0	0	0	112

LC/LNC	0	0	1	0	1	0	0	0	2

Carcinoid	0	0	3	0	1	13	0	0	17

Other	0	0	0	0	1	0	0	0	1

Susp.	0	0	1	0	0	0	0	0	1

Benign	6	0	14	1	5	2	0	84	112

Total	54	3	136	3	20	15	0	84	315


Parameter	n* (%)

Gender 	86

 Male	42 (48.8)

 Female	44 (51.2)

Age	86

 Range, 13.5–85.4 years	—

 Mean, 55.0 years	—

 Median, 57.2 years	—

Tumor size	78

 Range, 2.0–8.5 cm	—

 Mean, 4.9 cm	—

 Median, 5.0 cm	—

Tumor location	86

 Parasagittal-falcine	26 (30.2)

 Convexity	35 (40.7)

 Base	24 (27.9)

 Frontal/frontobasal	16 (18.6)

Tumor site	86

 Left	37

 Right	31

 Bilateral	18

Duration of signs/symptoms	80

 Range, 0–36 months	—

 Mean, 7.5 months	—

 Median, 4.0 months	—

Presenting signs/symptoms	83

 Headache	23 (25.9)

 Hemiparesis	22 (36.6)

 Seizures	20 (24.7)

 Behavior changes	12 (14)

 Cranial nerve palsy 	6 (11.1)

Behavior changes	83

 Present	30 (36.1)

 Absent	53 (73.9)

Edema	58

 Absent	10 (17.2)

 Mild 	31 (53.4)

 Severe	17 (29.3)

Cleavability	42

 Cleavable 	18 (42.9)

 Noncleavable	24 (57.1)


Antibody	Staining pattern	Clone	Antigen retrieval	Dilution	Source	Interobserver variability (kappa)

ER	Nuclear	SP1	EDTA pH 9	1:80	Immunologic	0.959

PR	Nuclear	PgR636	EDTA pH 9	1:500	Dako	0.961

MLH1	Nuclear	G168-15	EDTA pH 9	1:40	BD	0.894

PMS2	Nuclear	A16-4	EDTA pH 9	1:100	BD	0.800

MSH2	Nuclear	GB12	EDTA pH 9	1:20	Calbiochem	0.848

MSH6	Nuclear	EPR3945	EDTA pH 9	1:1000	Abcam	0.763

PTEN	Nuclear and cytoplasmic	6H2.1	EDTA pH 9	1:100	Dako	0.724

IMP3	Cytoplasmic	69.1	EDTA pH 9	1:50	Dako	0.912

β-Catenin	Membranous and cytoplasmic	14/β-catenin	EDTA pH 9	1:200	BD	0.911

L1CAM	Membranous	14.10	EDTA pH 9	1:100	BioLegend	0.921

Ki-67	Nuclear	MIB-1	Citrate pH 6.0	1:40	Dako	0.998

ARID1A	Nuclear	HPA005456	Citrate pH 6.0	1:100	Sigma	0.796

Stathmin	Cytoplasmic	3351	Citrate pH 6.0	1:50	Cell Signaling	0.824

P53	Nuclear	DO-7	Citrate pH 6.7	1:200	Immunologic	0.901

P16	Nuclear and cytoplasmic	MX007	HIER pH 8.0	1:60	Immunologic	0.779


Source	Average degree	Average distance	Clustering coefficient	Diameter

Figure 4 (NESG IDs)	19	2.7	0.43	6

Figure 4 (JCSG IDs)	45	1.5	0.46	3

Figure 4 (TB IDs)	6.7	2.0	0.46	4

Figure 5a (DNA pol IDs)	15	3.1	0.44	7

Figure 5b (RNA pol IDs)	13	3.1	0.44	7

Figure 6a (PSI IDs)	24	2.6	0.37	7

Figure 6b (PDB IDs 1)	6.1	3.9	0.31	9

Figure 6b (PDB IDs 2)	6.7	3.8	0.33	10


		Meters above sea level (masl)c		Mean annual temperature(matp)d	Mean annualrainfall (mar)e	Buffaloes tested	Seropositivity toT. gondii

Regiona	Municipalityb	Climate	No.	No.	%

Olmeca	Las Choapas	10	Warm	27.0°C	2900 mm	58	21	36.2

	Sayula de Alemán	80	Warm	27.0°C	1650 mm	156	93	59.6

	All					214	114	53.3

Papaloapan	Isla	60	Warm-humid	24.9°C	2316 mm	59	23	39.0

	J. Rodriguez Clara	95	Warm	25.0°C	1266 mm	66	28	42.4

	All					125	51	40.8

All						339	165	48.7


In silico SNP performance assessment	F0	F1	F2	F3	F4

# of SNPs	66,254	21,944	10,032	3,187	1,329

# of contigs with SNPs	9,579	5,058	2,057	1,651	998

# of SNPs submitted to the ADT	621	605	583	367	547

# of SNPs with ADT Score ≥ 0.6	598	572	557	353	525

% of SNPs with ADT Score ≥ 0.6	96.3	94.5	95.5	96.2	96.0

# of SNPs with ADT Score ≥ 0.9	314	316	297	177	291

% of SNPs with ADT Score ≥ 0.9	50.6	52.2	50.9	48.2	53.2

# of SNPs tested by the GGGT	96	96	108	108	288


abbreviation	muscle name	maximum isometric force (Fiso, N)	optimal fibre length (Lfopt, m)	tendon slack length (Ltsl, m)	pennation angle (°)

IC	M. iliotibialis cranialis	889	0.174	0.0451	0

ILa	M. iliotibialis lateralis (cranial part)	1265	0.174	0.2432	0

ILp	M. iliotibialis lateralis (caudal part)	1265	0.174	0.3099	0

AMB1	M. ambiens, ventral (pubic) head	971	0.039	0.1648	10

AMB2	M. ambiens, dorsal (iliac) head	1793	0.044	0.3941	15

FMTL	M. femorotibialis lateralis	1434	0.088	0.1746	15

FMTIM	M. femorotibialis intermedius	1706	0.084	0.1863	25

FMTM	M. femorotibialis medialis	1089	0.089	0.0603	30

ILFBa	M. iliofibularis (cranial part)	1254	0.176	0.2134	0

ILFBp	M. iliofibularis (caudal part)	1254	0.176	0.2733	0

ITCa	M. iliotrochantericus caudalis (cranial part)	897	0.064	0.0469	25

ITCp	M. iliotrochantericus caudalis (caudal part)	897	0.064	0.038	25

IFE	M. iliofemoralis externus	479	0.025	0.0667	25

ITM	M. iliotrochantericus medius	181	0.058	0.0241	0

ITCR	M. iliotrochantericus cranialis	330	0.053	0.0488	10

IFI	M. iliofemoralis internus	410	0.041	0.0533	0

FCM	M. flexor cruris medialis	1109	0.036	0.435	35

FCLP	M. flexor cruris lateralis pars pelvica	544	0.24	0.2449	0

ISF	M. ischiofemoralis	419	0.033	0.0816	15

PIFML	M. puboischiofemorales medialis + lateralis	816	0.089	0.1669	15

OM	M. obturatorius medialis	3124	0.055	0.1651	25

CFP	M. caudofemoralis pars pelvica (et caudalis)	1125	0.108	0.215	15

GL	M. gastrocnemius pars lateralis	1836	0.12	0.5818	20

GIM	M. gastrocnemius pars intermedius	798	0.125	0.507	15

GM	M. gastrocnemius pars medialis	3124	0.094	0.5957	20

FL	M. fibularis longus	2270	0.081	0.9633	20

FDL	M. flexor digitorum longus	1130	0.048	1.0366	20

FPPD3	M. flexor perforans et perforatus digitorum 3	1154	0.025	1.0737	30

FPD3	M. flexor perforans digitorum 3	3210	0.017	1.02	35

FPD4	M. flexor perforans digitorum 4	1434	0.026	1.004	20

FHL	M. flexor hallucis longus	469	0.04	1.0939	25

EDL	M. extensor digitorum longus	833	0.049	0.8512	30

TCf	M. tibialis cranialis (femoral head)	686	0.045	0.4791	25

TCt	M. tibialis cranialis (tibial head)	686	0.045	0.4215	25


Predictors (all T1 variables)	Odds Ratio	95% CI

Independent

Neighborhood crime	0.91	0.75–1.10

Neighborhood drug selling/use	1.39	1.16–1.66

Noxious neighborhood	1.03	0.90–1.19

Controls

Age	1.51	1.22–1.85

Sex (Ref = Male)	0.64	0.43–0.95

SES	1.08	0.88–1.30

Occasions of marijuana use	1.78	1.31–2.42


	Sense primer (5′ to 3′)	Anti-sense primer (5′ to 3′)

Human CCL19	CCAACTCTGAGTGGCACCAA	TGAACACTACAGCAGGCACC

Human CCL21	TGGCCTCTTACTCACCCTCT	GCCTCTTGATCCCCTTAGCC

Human CCR7	GCCTACGACGTCACCTACAG	GGCAGAAGAGTCGCCTATGG

Beta-actin	CCATCGTCCACCGCAAAT	TGTCACCTTCACCGTTCC

ALP	ATCTTTGGTCTGGCTCCCATG	TTTCCCGTTCACCGTCCAC

Human OCN	GGCAGCGAGGTAGTGAAGAG	CTGGAGAGGAGCAGAACTGG

Human COL1	GAG AGC ATG ACC GAT GG	GTG ACG CTG TAG GTG AA

IBSP	CGCCAATGAATACGACAATG	GATGCAAAGCCAGAATGGAT

Human VEGF-A	GAGCCTTGCCTTGCTGCTCTA	CACCAGGGTCTCGATTGGAT

Runx-2	GCAGCAACCCAGAAACACTT	AACACATGACCCAGTGCAAA

Osterix	AGAGGAGAGACTCGGGACAG	GAGTTGTTGAGTCCCGCAGA


Characteristics	ORT corner users, n(%)	ORT corner non-users, n(%)	p value

Age:			0.4905

 18-19 years	9(8)	11(9)

 20-29 years	48(44)	63(53)

 30-39 years	33(39)	35(30)

 40 and over	10(9)	9(8)

Education:			0.1048

 No formal education	59(54)	61(52)

 Primary or secondary education	33(30)	34(29)

 Tertiary education	10(9)	4(3)

 Other	8(7)	18(15)

Occupation:			0.0016*

 Housewives	35(32)	58(48)

 Petty traders	58(53)	55(46)

 Government employee	15(13)	2(2)

 Students	0(0)	2(2)

 Other	2(2)	2(2)

Religion: Muslim	106(96)	112(94)	0.4271

Marital Status: Married	101(92)	113(95)	0.3373

Number of children, Mean	4.2	3.3	0.0027*


	N = 137 patients (23 residents)

Physician's Use of Obesity Counseling

 % Counseled about Obesity (n)	85.4 (117)

 Mean Number of Counseling Practices1 (SD) (18 Items total)	5.3 (4.6)

5As

 Mean Number of Assess2 Practices (SD) (6 items)	2.2 (2.0)

 Mean Number of Advise3 Practices (SD) (4 items)	1.3 (1.3)

 Mean Number of Agree4 Practices (SD) (3 items)	0.7 (1.2)

 % Use Assist5 Practice (n) (1 item)	25.6 (35)

 Mean Number of Arrange6 Practices (SD) (4 items)	0.8 (0.4)


Characteristics	No. of patients (%)

Age (years)

 Median (range)	71.0 (65.0-81.0)

ECOG performance status

 0-1	108 (81.2)

 ≥ 2	25 (18.8)

BMI (kg/m2)

 < 30	96 (72.2)

 ≥ 30	37 (27.8)

WIC

 ≥ 1	52 (39.1)

 < 1	81 (60.9)

Baseline LVEF

 Median (range)	61% (47.0–69.0)

TNM stage

 I-II	39 (29.3)

 III	61 (45.9)

 IV	33 (24.8)

Anthracycline exposure

 Previous	49 (36.8)

 Concomitant	22 (16.5)

 None	62 (46.6)

Anthracycline cumulative dose (mg/m2)	116 (0-540)

Previous radiotherapy (thoracic wall)

 Yes	19 (14.3)

 No	124 (93.2)


Number of Procedures	< 200h	> 200h	p value

History Takings in Initial Patient Care	136.905	363.800	0.001075

Non-cast immobilizations	19.360	63.577	0.005303793

Cast immobilizations	32.811	102.160	0.000295235

Simple sutures	33.980	96.200	0.000032826369841

Donatti sutures	5.283	12.214	0.019836

Trauma Resuscitation Room visits	2.804	21.036	0.000045965


Country	Sample name	Latitude	Longitude

Poland	A	53° 50′02.83′′N	21° 03′30.36′′E

Poland	H	54° 23′21.42′′N	18° 28′42.18′′E

Germany	B	52° 13′09.87′′N	11° 42′25.14′′E

Germany	D	53° 25′51.60′′N	09° 46′39.78′′E

Denmark	I	56° 12′13.48′′N	08° 09′39.07′′E

Denmark	E	55° 56′16.98′′N	12° 28′35.70′′E

Sweden	F	58° 52′20.04′′N	14° 53′56.79′′E

Sweden	K	64° 36′27.31′′N	20° 57′04.32′′E

Ireland	G	53° 35′24.27′′N	08° 03′33.69′′W

UK	C	52° 29′17.12′′N	00° 55′59.12′′W

UK	J	52° 44′34.76′′N	01° 08′09.87′′W


	ExpressHMM	ANTM

Probe sensitivity	65%	44%

Novel probes predicted	65%	49%

Overlap exon Sensitivity	58%	58%

Novel transfrags predicted	27%	58%

5' Splice site sensitivity	16%	9%

3' Splice site sensitivity	16%	13%


Tandem repeat Family	Repeat Length	GC Content (%)	Genome Coverage (%)a	Consensus Sequenceb	Distribution

pBuM189	189	29	0.039	GCAAAAGACTCCGTCAATTA GAAAACAAAAAATGTTATAGTTTTGAGGATTAACC GGCAAAAACCGTATTATTTGTTATAT GATTTCTGTATGGAATACCGTTTTAGAA GCGTCTTTTATCGTATTACTCAGATATATCT TAAGATTTAGCATAATCTAAGAACTTTT TGAAATATTCACATTTGTCCA	D. buzzatii cluster species D. mojavensis

DbuTR198	198	34	0.027	AAGGTAGAAAGGTAGTTGGTGAGATAAACCAGAAAAA GAGCTAAAAACGGCTAAAAACGGCTAGAAAATAGCCA GAAAGGTAGATTGAACATTAATGGGCAAATGG ATGGATAAATAAGACTGGTCATCATCCAA TGAACAGAATCATGATTAAGAGATAGAAATA TGATTAGAAAGTAGGATAGAAAGGTTAGAAAG	D. buzzatii


Policosanol (Chemical formula)	Percent

Docosan-1-ol (C22-OH)	1.52 ± 0.24

Tricosan-1-ol (C23-OH)	2.12 ± 0.39

Tetracosan-1-ol (C24-OH)	2.02 ± 0.50

Hexacosan-1-ol (C26 -OH)	2.50 ± 0.16

Heptacosan-1-ol (C27−OH)	1.90 ± 0.25

Octacosan-1-ol (C28-OH)	75.44 ± 2.41

Nonacosan-1-ol (C29-OH)	2.55 ± 0.62

Triacontan-1-ol (C30-OH)	8.61 ± 1.20

Dotriacontan-1-ol (C32-OH)	3.34 ± 0.56


	Based on parent ATS report	Based on child ATS report

MVPA of trips during the times reported by the parent	U = 390.5, p = 0.02*	U = 596.5, p = 0.02*

ATS trips (n = 99) 2.46 min (2.83)	ATS trips (n = 128) 2.40 min (2.68)

Non-ATS trips (n = 13) 0.76 min (0.95)	Non-ATS trips (n = 15) 0.81 min (0.87)

Missing trips = 170 (60.3%)	Missing trips = 139 (49.3%)

MVPA of trips during the hour before the classes (7:56–8:55)	U = 665.5, p = 0.02*	U = 955.0, p = 0.01*

ATS trips (n = 104) 4.99 min (4.11)	ATS trips (n = 146) 4.99 min (3.91)

Non-ATS trips (n = 19) 2.55 min (1.69)	Non-ATS trips (n = 20) 2.59 min (1.60)

Missing trips = 159 (56.4%)	Missing trips = 116 (41.1%)


Case	Sex, Age (years)	Previous operations	Fusion length	ASF	Cause and further treatment

1	M, 62	Yes	2	Yes	Patient had persitant back pain postoperatively and paresthesia in the lower extremity. MRI showed an adjacent vertebral fracture leading to an elongation of the initial fusion of up to 4 segments and second explorative operation due to persistant paresthesia. No specific cause was identifed for this. Sensation returned to normal in the further course.

2	F, 67	No	6	Yes	Early adjacent failure was caused by an osteoporotic cut out of the upper uncemented pedicle screws. This led to an elongation of the fusion by two segements with cement-augmentation.

3	F, 74	No	5	Yes	After the inital dorsoventral fusion, an osteoporotic adjacent segment failure in the upper instrumented vertebra caused the need of a fusion extension of one more segment with pedicle screw cement augmention. Thereafter, the patient developed a wound dehiscence. This led to a further operation for wound debridement and closure.

4	M, 65	No	6	Yes	This adjacent segment failure included a pedicle fracture causing a transient paresis of the hip flexion requiring immediate screw removal and nerve exploration. There was no nerve root damage. The fusion was elongated by 2 levels. The muscle regained full function in the follow-ups.

5	F, 72	No	4	Yes	This patient had a screw misplacement as idenfied by the CT-scan. The screw was causing irritation of the nerve root and had a cut out through upper vertebral plate. This complex cause of adjacent segment failure and spinal nerve compression lead to an early revision and elongation by one segment.

6	M, 85	No	5	Yes	This patient showed during the primary operation a poor bone quality (osteoporosis) with the need to use cement augmentation of the upper instrumented vertebra. During the early mobilisation process, the patient suffered an adjacent vertebral fracture with progression needing a revision with elongation of 2 more segments with careful cement augmentation.

7	F, 67	No	6	Yes	Due to osteoporotic bone, the upper pedicle screws were cement augmented. However, the poor bone quality caused an osteoporotic fracture with nerve irritation needing a revision surgery with elongation of the fusion by 2 segments. Unfortunately thereafter, a wound healing defect caused a further superfical wound revision.

8	F, 83	No	3	Yes	Due to a collapse of the upper vertebral plate during the mobilisation process, a surgical revision with elongation of 1 segment with cement augmentation was necessary.


Active ingredient	Abbreviation/Pharmaceutical preparation	Trade name (US)	Manufacturer	Approval status (US)	Notes

Methylphenidate hydrochloride	MPH-MR08 (modified-release preparation)	RitalinR LA (using SODAS delivery system developed by Elan)	Novartis	available in US and Switzerland

Methylphenidate hydrochloride	MPH-TDS Patch for transdermal drug delivery (o.a.d); 12 h duration of action	DaytranaR DOT matrix transdermal technology	Shire (in license from Noven)	US approval (children age 6–12 years) April 2006; 2nd line to oral drugs	Skin sensitization reported in 13–22% of subjects wearing the patch; product had been deemed non-approvable by FDA before (April 2003)

Dexmethylphenidate, a non-racemic form of methylphenidate:	d-MPH (the active isomer of methylphenidate)	FocalinR	Novartis (in license from Celgene)	Approved in US

Dexmethylphenidate, a non-racemic form of methylphenidate:	d-MPH-ER (extended release formulation)	FocalinR XR	Novartis (in license from Celgene)	US approval (for "children, adolescents, and adults") May 2005

Lisdexamphetamine dimesylate	LisDEX; (pharmaceutical preparation with a o.a.d. dosing schedule)	NRP104	Shire (in license from New River Pharmaceuticals)	US approval (for children age 6–12 years) granted in 2007	Reduced abuse potential expected because amphetamine is linked to L-lysine and does no become active until metabolized in the gastrointestinal tract

Mixed amphetamine salts	MAS (immediate and extended release formulations	AdderallR, AdderallR XR	Shire	Available in US	Unlikely to be approved in Europe

ModafinilSuccessor compound: Armodafinil	MOD; dopamine reuptake inhibitor; effects on neuropetides possibleARM	SparlonR (licensed in US and UK as ProvigilR for narcolepsy)NuvigilR	Cephalon(SparlonR was planned to be co-promoted in the US by McNeil, a sister company of Janssen-Cilag)	After receiving a non-approvable letter for modafinil in ADHD from the FDA in August 2006, Cephalon refocused its R&D on armodafinil [61]	Suspected serious adverse events (skin rash/Stevens-Johnson syndrome) in association with modafinil


Current UK Vaccination Against Invasive Meningococcal Disease

Vaccine (Serogroups)	Year Introduced into schedule	Age given

B	2015	8 weeks, 16 weeks, 1 year

C	1999	1 yeara

ACWY	2015	14 years, University students 19–25 years


Cell type	AR expression (method)	Reference

Stem cells and progenitor cells

Hematopoietic stem cell	Yes (RT-PCR, IF)	(33, 34)

Common myeloid progenitor	Yes (RT-PCR)	(33)

Common lymphoid progenitor	Yes (RT-PCR)	(33)

Granulocyte-macrophage progenitor	ND

Common dendritic cell (DC) progenitor	ND

Megakaryocyte-erythroid progenitor	ND

Erythroblast	Yes (binding assay)	(32)

Early T cell progenitor	ND

Myeloid-derived cells

Megakaryocyte	Yes (IHC, RT-PCR, IF)	(37, 38)

Platelet	Yes (IF)	(38)

Erythroid cell (nucleated and enucleated)	Not expressed (IHC)	(37)

Monocyte	Yes (RT-PCR)	(37)

Macrophage	Yes (C+NC) (flow, IF, IHC, RT-PCR)	(16, 36, 37, 39)

Myeloid-derived DC	Not expressed (WB)	(40)

Myelocyte	Yes (IHC)	(37)

Metamyelocyte	Yes (IHC)	(37)

Neutrophil (band cell)	Yes (IHC)	(37)

Neutrophil (segmented)	Yes (IHC)	(37)

Mature eosinophil	Not expressed (IHC)	(37)

Basophil	ND

Mature mast cell	Yes (ImmGold)	(35, 41)

Lymphoid-derived cells

DN T cell	Yes (binding assay)	(42)

DP T cell	Yes (binding assay)	(42)

CD4+ T cell	Yes (C+NC) (flow, IF, binding assay)	(17, 28, 42)

CD8+ T cell	Yes (C+NC) (binding assay)	(17, 42)

Plasmacytoid DC	ND

Pro-B cell	Yes (WB)	(43)

Pre-B cell	Yes (WB)	(43)

Immature B cell	ND

Mature B cell	Not expressed (IHC, WB)	(37, 43)

Other

Thymic epithelial cells	Yes (IF)	(44)

Bone marrow stromal cells	Yes (IHC, WB)	(37, 43)


Query	Parameters inquired	Fluorescent wavelengths

1	FS, SS	2, 3 or 4

2	FS, SS, CD5	2, 3 or 4

3	FS, SS, CD5, CD20	2, 3 or 4

4	FS, SS, CD5, CD20, CD19, CD34	4


AKI progression	Number of patients	ICU mortality	p

AKI I (n = 4259)

with rising creatinine values	1995 (46.8%)	522 (26.2%)	< 0.0001

with falling creatinine values	2264 (53.2%)	334 (14.8%)

AKI II (n = 857)

with rising creatinine values	439 (51.2%)	157 (35.8%)	< 0.0001

with falling creatinine values	418 (48.8%)	65 (15.6%)

AKI III (n = 2782)

with rising creatinine values	639 (23%)	318 (49.8%)	< 0.0001

with falling creatinine values	296 (10.6%)	62 (20.9%)

AKI III based on RRT criteria	1847 (66.4%)	999 (54.1%)

AKI I/AKI II progressing to AKI III	1664 (59.8%)	796 (47.8%)	p = 0.029

AKI III without prior AKI I/AKI II	1118 (40.2%)	583 (46.2%)


Yes (+)	LBP+	LBP+	LBP−	LBP−	Missing answers on pain 	LBP	SP 	LBP 	SP

No (−)	SP+	SP−	SP+	SP−	PIW+	PIW+	PINT+	PINT+

Number of workers n (%)	238 (45)	101 (19) 	47 (9)	79 (15)	60 (12)	156 (30)	96 (18)	180 (34)	147 (28)


Zones	Most Used Pesticides (Top 5) in %	Cumulative %

1	2	3	4	5

Obala	Ridomil (8%)	Onex (6.3%)	Actara (5.7%)	Callomil (5%)	Lamida Gold, Parastar and Plantomil (4.7% each)	39.4

Foumbot	Gramoxone (12.6%)	Timide (7.4%)	K-optimal (7.1%)	Roundup (6.7%)	Cigogne and Pencozeb (4.1% each)	42

Santa	Gramoxone (12.7%)	Banko (12%)	Pencozeb (8%)	Roundup and Mancozan (6.7% each)	Parastar (4.7%)	50.8

Njombe–Penja	Gramoxone (12.8%)	Pyriforce (9.4%)	Glyphader (7.2%)	Ridomil and Supraxone (4.7% each)	Roundup and Capsidor (4.3% each)	47.4

Ngong–Garoua	Roundup (23.7%)	Atrazine (20.1%)	Gramoxone (15.9%)	Diuron (14.8%)	Biosec Roundup 720 (3.2%)	80.9


F0	F1	F2	F3

Hip center speed (m/s)	Shoulder center speed (m/s)	Right hip speed (θ/s) Frontal plane	Right hip angle (θ) Frontal plane


Variables	GLM resultsinteraction effecta	Statistical changes over time(p value)	Adjusted mean differences between groups over timeb(Clinical changes)

	Group * Time	T1 → T2	T1 → T2

EORTCQLQ-C30:

Global quality of life	12.5	.000	+8.2

Functional scales:

Physical	118.5	.000	- 16.2

Role	30.1	.000	- 11.0

Emotional	9.8	.002	+8.5

Cognitive	7.9	.005	- 6.0

Social	8.4	.004	- 7.0

Symptom scales:

Fatigue	22.7	.000	+12.0

Nausea/vomiting	4.7	.030	+3.4

Pain	13.3	.000	+8.6

Dyspnea	0.6	.419	+1.7

Insomnia	1.7	.184	+4.0

Appetite loss	0.1	.707	- 1.0

Constipation	8.6	.004	+7.5

Diarrhea	0.4	.545	- 1.1

Financial difficulties	51.7	.000	+21.7

Sense of Coherence	17.3	.000	- 6.5

Spiritual Perspective Scale	31.0	.000	- 6.6

Religious Coping (+)	9.8	.002	- 6.5

Religious Coping (−)	3.5	.060	+4.3


Days in EB formation	Post EB differentiation	Differentiation conditions	Chondrogenic markers studied	Cells line(s)	Reference

5	Encapsulation of EBs in PEG hydrogel for 17 days	The EBs in hydrogel were differentiated in presence of chondrogenic medium (CM) treated with BMP-2 and TGF-β1	Type I, II, X collagen, and osteocalcin. Proteoglycans content measurement	Mouse-D3 and human-BG03	[12–15]

N/R	EB cells were seeded on ceramic particles	Cells on the ceramic scaffold was differentiated in vitro for 21 days in CM supplemented with TGF-β3 and 21 days of in vivo maturation	Morphology was studied and proteoglycans content was analyzed	Mouse-IB10, human MSC, and Goat MSCs	[4]

7 RA from day 2	EBs were plated	RA-treated EB outgrowth culture was treated with TGF-β3	D15: proteoglycans, Col2a1, Sox9, Col10a1 and MMP13	Mouse-CGR8, E14Tg2a, EFC1	[16]

28	After 4 weeks the EBs were dissociated and self-assembled for additional 4 weeks	EBs were differentiated in chondrogenic medium supplemented with combinations of TGF-β1, TGF-β3, BMP-2, and IGF-1 (100 ng/mL)	Sox9, Col1a1, Col2a1	Human-BG01V	[17]


	Anteparturm hemorrhage	Transverse lie	Placenta previa	Breech presentation	Ectopic pregnancy	Twins	Poly /oligo hydromnious

Very confident	23.3	13.3	10	13.3	3.3	13.3	0

Confident	50	60	23.3	56.7	16.7	60	33.3

Not confident	10	13.3	46.7	23.3	40	27.3	43.3

Cannot measure/diagnose	16.7	13.3	20	6.7	40	0	23.3


Bacterial strain	Source	Reference

L. sakei 23K	Sausage	[66,67]

L. sakei MF1053	Fermented fish (Norwegian "Rakfisk")	[30]

L. sakei LS 25	Commercial starter culture for salami sausage	[68]

L. sakei Lb790x	Meat	[69]

L. sakei LTH673	Fermented sausage	[70,71]

L. sakei MF1328	Fermented sausage	[30]

L. sakei MF1058 (TH1)	Vakuum-packed cooked meat, protective culture	[9,10]

L. sakei CCUG 31331a (DSM 15831b, R 14 b/a)	Fermented sausage, type strain for L. sakei subsp. carnosus	[27,72]

L. sakei DSM 20017b (ATCC 15521c)	Sake, alcoholic beverage made by fermenting rice, type strain for L. sakei subsp. Sakei	[27]

L. sakei Lb16 (Lb1048d, CCUG 42687a)	Minced meat	[31,73]


Gene 	Sequence	bp

Beclin-1	Sense 5′ CCAGATGCGTTATGCCCAGAC 3′ Anti-sense 5′ CATTCCATTCCACGGGAACAC 3′	149

mTOR	Sense 5′ AAACTGCACGTCAGCACCATC 3′ Anti-sense 5′ AGCCGTCTCAGCCATTCCA 3′	192

ATG5	Sense 5′CCATCAATCGGAAACTCATGGA 3′ Anti-sense 5′ATCTGCAGCCACAGGACGAA 3′	128

ATG7	Sense 5′ CTGTAACTTAGCCCAGTACCCTGGA 3′ Anti-sense 5′TACGGTCACGGAAGCAAACAAC 3′	113

Actin	Sense 5′TGGCACCCAGCACAATGAA 3′ Anti-sense 5′CTAAGTCATAGTCCGCCTAGAAGCA 3′	128


	Educationa	Household income (LICO)b	Neihgbourhood SEPc	Combined SEPd

A- Maternal and infant health status indicators

1. Preterm Birth	+	NS	NS	+ (*) (low-high)

2. Small for gestational Age	NS	+	+	+ (low-low)

3. Self rated health	+	+	+	+ (low-low)

4. Postpartum Depression	+	+	+	+ (low-low)

5. Pre-pregnancy BMI (<18.5)	+	+	+	+ (low-low)

6. Pre-pregnancy BMI (>24.5)	+	+	NS	+ (low-high)

B- Prenatal care

7. First prenatal care visit	+	+	+	+ (low-low)

8. Timing of ultrasound	-	NS	NS	NS

9. HIV testing (no)	NS	-	NS	+ (low-low)

10. Received enough information during pregnancy	+	+	+	+ (low-low)

11. Weight gained during pregnancy (kg) - (Below recommended range)	+	+ (*)	NS	+ (*) (low-high)

12. Weight gained during pregnancy (kg)-more (Above recommended range)	+	+	NS	+ (low-high)

C- Labor and deliveryexpereinces

13. Type of birth (caesarean)	NS	-	NS	+ (low-high)

14. Epidural for a vaginal birth	-	-	NS	+ (low-high)

15. Shaving for a vaginal birth	+	+	+	+ (low-high)

16. Position for vaginal birth (not laying flat)	NS	+	+	+ (low-low)

D- Medical care during the neonatal period

17. Infant hospital readmission	NS	NS	NS	NS

18. Infant needing non-routine neonatal care after discharge?	-	-	-	- (low-low)

19. Baby admitted to NICU after birth	NS	NS	NS	NS

20. Length of hospital stay after caesarean birth (More than average)	NS	NS	+	+ (high-low)

21. Length of hospital stay after vaginal birth (More than average)	+ (*)	NS	NS	NS

E- Postpartum infant care & maternal reflections on the overall experience of health care

22. Any breastfeeding at 3 months	+	+	-	+ (low-high)

23. Any breastfeeding at 6 months	+	+	-	+ (low-high)

24. Overall experience of labor and birth	NS	+	NS	+ (low-high)

25. Satisfaction with previous aspects of maternity care	+	+(*)	NS	NS


Demographic Variables	Number

Ages

15-19	2

20-24	2

25-29	2

30-34	1

35-39	2

40-44	1

45-49	0

Total	10

Educational Attainment

None	1

Grades 1-4	1

Grades 5-8	3

Grades 9-12	5

Tertiary education	0

Total	10

Age at first birth

15-19	6

20-24	3

25-29	1

30-34	0

35-39	0

40-44	0

45-49	0

Total	10

Marital Status

Single	8

Customary marriage	0

Civil Marriage	0

Cohabiting	2

Total	10

Number of live births

0-2	2

04-Mar	6

5+	2

Total	10

Employment Status

Unemployed	7

Employed	2

Other: e.g. self-employed as petty trader	1

Total	10


Agent*	Time (s)	Capping efficiency

Acetic anhydride	15	60 ± 4%

Acetic anhydride	30	81 ± 2%

Acetic anhydride	60	92 ± 2%

Acetic anhydride	120	95 ± 2%

DMT-dT	15	91 ± 2%

DMT-dT	30	94 ± 1%

DMT-dT	60	97 ± 1%


		Abnormalcardiometabolic profile	Normalcardiometabolic profile	TOTAL

Untreated	"Normal" weight(BMI = 18.5 - 24.9)	23.5%(16.3 million people)b	76.5%(53.0 million people)	100%(69.3 million people)

Treated	"Overweight"(BMI = 25.0 - 29.9)	48.7%(34.1 million people)	51.3%(35.9 million people)c	100%(70.0 million people)

	"Obese"(BMI ≥ 30.0)	68.3%(42.0 million people)	31.7%(19.5 million people)c	100%(61.5 million people)

TOTAL	46%92.4 million people	54%108.4 million people	100%200.8 million people


	Number of controls

	10	60	110	160	210

Percentage of results that included the mutation (%)	100	100	100	100	100

Percentage of mutation loci in the top hit (%)	46	43	37	38	37

Mean length of haplotypes (number of SNPs)	629	546	441	410	383


Cantilever ID	L μm	-Sphere -material	Sphere number	Sphere diameter, μm	Resonance Frequency -kHz	ΔLm μm

DNP 6A	108	Gold	–	0	62.8	–

		19300	1	3.8	56.0	+1.9

		kg·m−3	2	5.7	46.8	−1.4

			3	9.5	31.2	−1.1

			–	0	62.8	–


All Sounds > Baseline

Region	Number of Voxels

Right Frontal Cortex	14335

Frontal pole

Frontal orbital cortex

Middle frontal gyrus

Pars opercularis

Pars triangularis

Right Temporal Cortex	2243

Middle temporal gyrus, posterior division and temporoccipital part

Superior temporal gyrus, posterior division

Heschl’s gyrus

Left Temporal Cortex	874

Middle temporal gyrus, posterior division

Superior temporal gyrus, posterior division

Heschl’s gyrus

Left Frontal Pole	48


	General evidence	Managerial Accounting tools	HRM tools	ICT tools	Outcomes	Open issues

Progressive patient care model	In some contexts implementation by law (e.g. Tuscany)Great autonomy of organizations on how to implement modelForms of implementation:poles; separation elective/unscheduled/emergency patients; distinct inpatient/outpatient pathways; emphasis on ED; pool beds; centralization of functions	Integrated Planning, Budgeting and Control systems (e.g. BSC)In concrete, however, MA tools not aligned to model (e.g. budgets still assigned to clinical wards)	New professional roles and a general reassignment of responsibilities (nurses and physicians)Need for:Competency based model;Separate professional/managerial career paths;Multi-source and 360° feedback system	Integrated electronic health records, to be jointly used and updated by physicians and nurses	Improved efficiency indicatorsIncreased patient satisfaction (medical and/or nursing tutor)More coordination between medical and surgical staffBetter implementation of clinical pathwaysLack of evidence in terms of improved clinical outcomes	Effective allocation of nurses to different settingsCorrect triage activity in ED and efficient allocations of patientsDesirability of medical day- or week- hospitalsInvolving professionals and of overcoming cultural barriersDefinition of clear repartition of responsibilities among professionals

Patient centered approach	The most analyzed aspect of PC is related to continuity of care among different settings (poorly explored within hospitals)An exception: analysis of general process improvements within EDs		New professional roles in hospitals (e.g. liason nurse)	ICT tools should ideally:prioritize information and detect individuals’ contextual situations,promote stronger inter-professional relationships with adequate exchange of information,enable interoperability and scalability between and within institutions,function across different platforms.Few pioneer experiences (e.g. Shared care platform)ICT tools still rudimental if compared to their potential	Significant relationships between specific elements of PC and outcomes, or between PC approach in general and a reduced ED utilization.Liason activities are associated with slightly higher (not significant), quality care transitions.Greater patient satisfactionImproved communication among professionalsGeneral evidence about the effects of PCC on clinical outcomes very limited	Poor attention of literature to PC within hospitalsNecessary switch from hospital information systems to health care information systemsNon exhaustive informationIndividuals involved are not tracedLack of tools to clearly assess PC

Lean approach	Application of various features of lean such as new employee roles, staffing and scheduling, communication and coordination, workspace layout, process design etc.Application of lean tools within settings (EDs, ORs, outpatient settings)Only few examples of lean applied to pathways		Staff empowerment and “bottom-up approach”, by allowing the frontline staff to identify problems and come up with appropriate solutions		Many examples of improvement in efficiency indicatorsFewer examples of improvement in clinical outcomesA number of studies find inconsistent the evidence about lean’s contribution to higher organizational performance	Lean is often felt to be “a constellation of disjointed and poorly connected activities”Lack of “system-wide” improvement philosophyThe “bottom-up approach” is not fully implemented in concrete and barriers to implementation persistNeed of more formation for inter-professional collaboration


Unigene No.	Gene name	Copies	%*

Fetal pituitary

Hs.1905	prolactin+#	312	9.46

Hs.119689	glycoprotein hormones, alpha +#	146	4.43

Hs.115352	growth hormone 1+#	48	1.46

Hs.274460	olfactory receptor 5V1#	48	1.46

Hs.195453	ribosomal protein S27+#	24	0.73

Hs.75415	beta-2-microglobulin+#	22	0.67

Hs.70312	cytochrome c oxidase 7A2+#	15	0.46

Hs.315164	hypothetical protein#	14	0.42

Hs.83484	sex determining region Y-box 4#	8	0.24

Hs.7917	DKFZP564K247 protein#	7	0.21

Hs.273385	guanine nucleotide binding protein alpha+#	7	0.21

Hs.165590	ribosomal protein S13#	7	0.21

Hs.131814	tankyrase#	7	0.21

Hs.173912	eukaryotic translation initiation factor+	6	0.18

Hs.119222	suppression of tumorigenicity 13+#	6	0.18

Hs.177530	ATP synthase+	5	0.15

Hs.177656	calmodulin 1+	5	0.15

Hs.241429	cDNA DKFZp586C1923#	5	0.12

Hs.330994	RAB9#	4	0.12

Hs.46328	fucosyltransferase 2#	4	0.12

Adult pituitary

Hs.115352	growth hormone 1+#	358	6.09

Hs.1905	prolactin+#	288	4.9

Hs.1897	proopiomelanocortin#	46	0.78

Hs.181165	eukaryotic translation elongation factor1#	45	0.77

Hs.273385	guanine nucleotide binding protein AS1+#	44	0.75

Hs.65149	growth hormone 2#	42	0.71

Hs.279789	glucose phosphate isomerase#	41	0.7

Hs.119689	glycoprotein hormones, alpha+#	37	0.63

Hs.77385	myosin, light polypeptide 6+#	30	0.51

Hs.278959	galanin-related peptide LOC51083#	25	0.43

Hs.247474	hypothetical protein FLJ21032#	21	0.36

Hs.180450	ribosomal protein S24#	20	0.34

Hs.155482	hydroxyacyl glutathione hydrolase#	19	0.32

Hs.76053	DEAD/H box polypeptide 5#	19	0.32

Hs.75360	carboxypeptidase E+#	18	0.31

Hs.112844	maternally expressed 3#	16	0.27

Hs.117950	phosphoribosylaminoimidazole carboxylase#	16	0.27

Hs.119598	ribosomal protein L3#	16	0.27

Hs.5464	skeletal muscle abundant protein#	16	0.27

Hs.179526	thioredoxin interacting protein #	15	0.26


Variable	PFNA (n = 72)	DHS (n = 70)	P value

Total complications	15	31	0.003

 Patients affected	15 (20.8%)	31 (42.9%)	0.003

Medical complications	3	5	0.442

 Patients affected	3 (4.2%)	5 (7.1%)	0.442

Urinary tract infection	1	1	1.000

Pulmonary embolism	0	2	0.241

Atrial fibrillation	2	0	0.497

Acute renal failure	0	2	0.241

Orthopaedic complications	12	26	0.011

 Patients affected	12 (16.7%)	26 (37.1%)	0.011

Periprosthetic fracture	3 (4.2%)	11 (15.7%)	0.021

Prosthetic instability	1	2	0.617

Dislocation	1	3	0.363

Limb length discrepancy (>2.5 cm)	1	2	0.617

Abductor tendon deficiency	2	2	1.000

Heterotopic ossification	1	1	1.000

Intraoperative nerve injury	1	1	1.000

Aseptic loosening	0	1	0.241

Periprosthetic infection	2	2	1.000


WHO AFRO SLIPTA Checklist Audit Score Sheet (Section)	Total Points

Section 1: Documents & Records	25

Section 2: Management Reviews	17

Section 3: Organization & Personnel	20

Section 4: Client Management & Customer Service	8

Section 5: Equipment	30

Section 6: Internal Audit	10

Section 7: Purchasing and Inventory	30

Section 8: Process Control and Internal & External Quality Audit	33

Section 9: Information Management	18

Section 10: Corrective Action	12

Section 11: Occurrence/Incident Management & Process Improvement	12

Section 12: Facilities and Safety	43

Total Score	258


	Left hemisphere	Right hemisphere

V1

Smooth objects	0.92 ± 0.09	0.82 ± 0.09

Textured objects	1.63 ± 0.11	1.50 ± 0.13

V2

Smooth objects	0.92 ± 0.06	0.88 ± 0.06

Textured objects	1.33 ± 0.07	1.28 ± 0.09

V3

Smooth objects	0.98 ± 0.09	0.92 ± 0.06

Textured objects	1.26 ± 0.11	1.18 ± 0.09

LOC

Smooth objects	0.99 ± 0.09	1.00 ± 0.08

Textured objects	0.81 ± 0.09	0.82 ± 0.06

FFA

Smooth objects	0.96 ± 0.17	1.10 ± 0.10

Textured objects	0.79 ± 0.19	1.05 ± 0.15


Study	Main perspective	Subject	Method

Hansen, Hegrenes, Larsen, Sehested, & Stokstad, 2005	Biological Economic	Financial impact of technical herd performance indicators	Mathematical and statistical modelling

Kristensen, Østergaard, Krogh, & Enevoldsen, 2007	Biological Economic	Financial impact of technical herd performance indicators	Mathematical modelling

Kristensen & Enevoldsen, 2008	Managerial	Farmers’ goals, beliefs attitudes and behaviour	Interviews and survey

Kristensen, Nielsen, Jensen, Vaarst, & Enevoldsen, 2008	Biological Managerial	Risk for metritis. Veterinarians perceptions and decision making	Interviews combined with quantitative analysis of herd data

Jansen, van den Borne, Renes, van Schaik, Lam, & Leeuwis, 2009	Biological Managerial	Farmers’ attitudes and behaviour	Survey

Lastein, Vaarst, & Enevoldsen, 2009	Managerial	Veterinarians’ perceptions and decision making	Field observations and interviews

Vaarst & Tind Sørensen, 2009	Biological Managerial	Dairy farmers’ perceptions and attitudes related to calf management	Semi-structured interviews

Van Asseldonk, Renes, Lam, & Hogeveen, 2010	Managerial	Farmers’ perceptions, intentions, actions and decision makings	Interviews


Parameter	Value	Parameter	Value

Radio chip	CC 2420	TsRxWait	2.2 ms

Transmit power (0 dBm)	57.42 mW	TsAck (26 bytes)	0.832 ms

Receive power	62.04 mW	TsCCA	0.128 ms

Listen power	62.04 mW	TsRxTx (TxRx turnaround)	0.192 ms

TsMaxPacket (133 bytes)	4.256 ms


	RD CsA (n = 99)	ST CsA (n = 100)

Everolimus dose (mg/day)

Month 1	1.3 ± 0.5	1.4 ± 0.6

Month 6	1.4 ± 0.6	1.3 ± 0.5

Everolimus trough concentration (ng/mL)

Month 1	5.8 ± 3.6	5.8 ± 2.5

Month 6	4.8 ± 1.7	5.3 ± 2.3

Cyclosporine dose (mg/kg/day)

Month 1	3.8 ± 1.3	4.0 ± 1.4

Month 6	2.5 ± 1.0	2.8 ± 0.8

Cyclosporine trough concentration (ng/mL)

Months 1-2	195 ± 78	209 ± 87

Month 6	120 ± 63	154 ± 68

Cyclosporine C2 concentration (ng/mL)

Months 1-2	742 ± 272	693 ± 244

Month 6	566 ± 278	707 ± 284

Steroid dosea	0.50 ± 1.40	0.32 ± 0.25

Induction therapy

Antithymocyte globulin	60 (60.6%)	61 (61.0%)

Interleukin-2 receptor antagonist	21 (21.2%)	20 (20.0%)


Features	Missense mutations identified as divergent variants based on the analysis of whole-genome sequence datasets from Churra and Australian Merino samples

SNP position (Oar_v3.1)	52,429,848	37,308,727	37,3557,21	37,356,400

Chromosome	2	6	6	6

dbSNP_ID	rs160159505	rs159958168	rs419074913	rs159958380

Gene	NPR2	NCAPG	LCORLa	LCORLa

Ref. (Texel Oar_v3.1) → Altb	T → C	C → T	T → A	A → T

Position in CDS	c.2540	c.1754	c.4321c	c.3642c

Base pair substitution in CDS	T → C	C → T	A → T	T → A

Breed (mutant allele)d	Merino	Merino	Churra	Merino

Codon change	cAc → cGc	TCC → TTC	ATA → TTA	GAT → GAA

Amino acid change	Histitine (H) → Arginine (R)	Serine (S)→ Phenilalanine (F)	Isoleucine (I)→ Leucine (L)	Aspartate (D) → Glutamate (E)

Protein change	NPR2_His847Arg	NCAPG_Ser585Phe	LCORL_Ile1441Leu	LCORL_Asp1214Glu

Functional impact (ensemblVEP_Oarv3.1)	Moderate	Moderate	Moderate	Moderate

Functional impact (Polyphen-2)	Benign	Benign (score = 0.252; sensitivity: 0.91; specificity: 0.88)	Benign	Benign

Functional impact (SIFT_Oarv3.1)	Tolerated	Deleterious	Tolerated (low confidence)	Tolerated

Properties of wild aminoacid	Moderate hydropathy, charge “+”	Hydrophilic, polar, no charge	Hydrophobic, no charge	Hydrophilic, charge “−”

Properties of mutant aminoacid	Hydrophilic, charge “+”	Hydrophobic, apolar, no charge	Hydrophobic, no charge	Hydrophilic,, charge “−”

Churra genotypes	TT (15)	CC (14), CT (1)	AT (1), TT (14)	AA (14), AT (1)

Australian Merino genotypes	CC (9), TC (4)	TT (9), TC (3), CC (1)	AA (9), AT (3), TT (1)	TT (9), TA (3), AA (1)


Condition	Number (%) of cases	Mean number of coded diagnoses by coding volume	Mean number of coded diagnoses by employment status	Hospital level

		Low	High	Part time	Full time	Non tertiary	Tertiary

Most complexDiabetes with complications	2007(0.5%)	7.9	7.9	7.7	7.9	7.0	9.5

Alcohol abuse	2511(0.6%)	5.3	5.4	5.6	5.3	5.1	5.9

Diabetes uncomplicated	1802(0.4%)	5.0	4.9	4.4	5.2	4.4	6.8

Depression	5860(1.4%)	4.4	4.3	4.7	4.2	4.2	4.7

Calculus of ureter	3616(0.9%)	1.5	1.7	1.5	1.7	1.6	1.4

Singleton born in hospitalLeast Complex	38,307(9.1)	1.3	1.6	1.5	1.2	1.6	1.1


Sample	Accession no.	ciHHV-6	Integration sitea	Population or country

LEI-1501b	KT355575	A	19q	Leicester area (England)

HAPMAP NA18999	KY316047	A		Japan

3A-10q26.3c	KY316049	A	10q26.3 and junction isolated by PCR	Southeast England

GLA_4298d	KY316056	A		Newcastle (England)

GLA_15137e	KY316055	A		Scotland

GLA_ 25506e	KY316054	A		Scotland

7A-17p13.3c	KY316048	A	17p13.3	Southeast England

HGDP00092	KY316037	B		Balochi (Pakistan)

HGDP00813	KY316036	B		Han (China)

HGDP01065	KY316035	B	Junction isolated by PCR	Sardinia (Italy)

HGDP01077	KY316034	B	Junction isolated by PCR	Sardinia (Italy)

HAPMAP NA07022 (CEPH 1340.11)	KY316039	B		Utah Mormon (north European)

HAPMAP NA10863 (CEPH-1375.02)	KY316038	B		Utah Mormon (north European)

4B-11p15.5c	KY316044	B	11p15.5	Southeast England

BAN519f	KY316043	B		Banff (Scotland)

COR264f	KY316042	B		Cornwall (England)

CUM082f	KY316041	B		Cumbria (England)

DER512f	KY316040	B	Junction isolated by PCR	Derbyshire (England)

2B-9q34.3c	KY316045	B	9q34.3	Southeast England

1-ciHHV-6Bc	KY316046	B	Junction isolated by PCR	Southeast England

LEI-ALD	KY316033	B		Leicester area (England)

ORCA1622	KY316031	B		Orkney

ORCA1340	KY316032	B		Orkney

ORCA3835	KY316030	B		Orkney

GLA_3986d	KY316053	B		Newcastle (England)

GLA_29221e	KY316052	B		Scotland

GLA_34108e	KY316051	B		Scotland

GLA_35629e	KY316050	B		Scotland


Collaborative Problem Solving Skills	N	Mean	Standard Deviation

Social Skills	Participation	210	3.07	1.316

Perspective Taking	210	3.09	1.347

Social Regulation	210	3.10	1.364

Cognitive skills	Task Regulation	210	3.00	1.334

Knowledge Building	210	2.92	1.326


	Recall

	25 %	50 %	75 %

Precision to benign	82 %	66 %	52 %

Precision to malignant	86 %	74 %	62 %

	Precision (n=30)

Benign	85 %

Malignant	87 %


		<underline>Factor Loadings</underline>*

Items		Benefits	Barriers	Unique Variance

Osteoporosis drug treatment benefits†

1	Drug treatments can help to build strong bones	0.80	0.07	0.36

2	You would feel good about taking drug treatments to prevent osteoporosis	0.94	-0.06	0.11

3	Drug treatments can cut down the chances of broken bones	0.87	0.10	0.25

6	You would consider taking drug treatments to prevent broken bones	0.90	-0.06	0.17

11	If your doctor advised you to, you would take drug treatments to prevent broken bones	0.78	-0.12	0.36

Drug treatment barriers†

8‡	You are taking too many medications	-0.12	0.85	0.25

9‡	You have stomach problems that limit your ability to take drug treatment	0.14	0.56	0.69


 	Category

Occupation	Documentation (N = 38) fraction %	Interactions (N = 36) fraction %	Adverse effects (N = 16) fraction %	Pregnancy and breastfeeding (N = 9) fraction %	Contraindications (N = 1) fraction %

Physicians (N = 54)	23/54 42.6	15/54 27.8	12/54 22.2*	3/54 5.6	1/54 1.9

Pharmacists (N = 33)	10/33 30.3	20/33 60.6**	1/33 3.0	2/33 6.1

Midwifes (N = 3)	 	 	 	3/3 100.0

Nurses (N = 2)	1/2 50.0	 	 	1/2 50.0

Other (N = 8)a	4/8 50.0	1/8 12.5	3/8 37.5


	Overall frequency	Uptake of facility-based delivery

N	%	%	PRu	95 % CI	PRa	95 % CIa

Self-reported HIV status				(p < 0.001)	(p < 0.001)

Not tested / unknown status before delivery	686	(7.8)	44.4	0.56	(0.49–0.64)	0.60	(0.54–0.68)

Self-reported HIV-negative before delivery	7067	(80.3)	79.3	1.00		1.00

Self-reportedHIV-positive before pregnancy	584	(6.6)	82.2	1.04	(0.99–1.09)	1.04	(1.00–1.09)

Self-reported HIV-positive during pregnancy	459	(5.2)	80.4	1.01	(0.97–1.06)	1.05	(1.01–1.09)


	Aneurysms	Pseudo-aneurysms

Location	3% posterior	Posterior or inferior

Echocardiography

 Anatomy	Thinned myocardium	Ruptures

 Contractility	Non contractile	Dyskinesia

Consequences/Complications	Congestive heart failureEmbolic eventsVentricular arrhythmias

Therapy	Medical or Surgical therapy	Surgery

Surgical risk	Dubious	Lower than medical therapy


Impression technique	n	Internal discrepancy to master model (μm)

Premolar 34	Molar 36	FDP 34–36

Mean	(SD)	Mean	(SD)	Mean	(SD)

Conventional	10	100	6.7	127	15.7	117	11.6

Digital	10	91	8.8	95	8.5	93	8.2

Significance (2-tailed) (P < 0.01)	 	0.016	 	<0.001	 	<0.001


District	No. of IDUs	Male	Female	Married	Education	Economic status

Peshawar	100	98	2	62

Kohat	60	60	-	30	Basic: 98%	< 1$/day: 95%

Mardan	40	40	-	28	High: 2%	Well off: 5%

Total	200	198	2	120


Gene	Primer	Annealing Temp (° C)

Fshr	F: TGGAGGCGGCAAACCTCTGAAC	65

R: TCTGGCTTTGGCGAGCAGGTC

Oct-4A	F: CCATGTCCGCCCGCATACGA	61

R: GGGCTTTCATGTCCTGGGACTCCT

Total	F: CCTGGGCGTTCTCTTTGGAAAGGTG	68

Oct-4	R: GCCTGCACCAGGGTCTCCGA

Nanog[34]	F: CAGGAGTTTGAGGGTAGCTC	61

R: CGGTTCATCATGGTACAGTC

Stella	F: ACGCTTTGGATGATACAGACGTCC	67

R: GCGCTTTGAACTTCCCTCCGGA

Fragilis	F: GGGGTGACTGAGCTGGGGGAA	65

R: TGTCCCTAGACTTCACAGAGTAGGC

Nobox	F: AGGGTGCTGAGAGGGTGGCAG	66

R: GGCGATACTAGTGCCCCAGGAC

HoxA10	F:CACTTGTCCGGCACCCCTTCG	65

R: TTCGCCTTTGGAACTGCCTTGAC

Mvh	F: AGTGGAAGTGGTCGAGGTGGT	61

R: TGCCGGTGGTGCATCATGTCC

Scp3	F: TGTTGCAGCAGTGGGAACTGGAT	68

R: CCATCTCTTGCTGCTGAGTTTCCA

Dmc-1	F: TGGGGAATTGGCTGAACGCC	68

R: CAGGCATCTCGGGGCTGTCATAA

Stra8	F: GTTTCCTGCGTGTTCCACAAG	61

R: CACCCGAGGCTCAAGCTTC

18s	F:GGAGAGGGAGCCTGAGAAAC	61

R: CCTCCAATGGATCCTCGTTA

Gapdh[34]	F: GTCCCGTAGACAAAATGGTGA	58

 	R: TGCATTGCTGACAATCTTGAG


	Cohorta	Age (years)	Effect	Measurement	Reference

Verbal functions

 Vocabulary	Oswego	3	↓	MSCA Word Knowledge	Stewart et al. 2003b

		4.5	–	MSCA Word Knowledge	Stewart et al. 2003b

	Michigan	4	–	PPVT	Jacobson et al. 1990

		11	↓	WISC-R Vocabulary	Jacobson and Jacobson 1996

		11	↓	WRMT Word Comprehension	Jacobson and Jacobson 1996

	Faroe Islands	7	–b	BNT	Grandjean et al. 2001

 Verbal comprehension	Netherlands	3.5	↓c	RLDS	Patandin et al. 1999b

 Reading comprehension	Michigan	11	↓	WRMT Reading Comprehension	Jacobson and Jacobson 1996

 Verbal abstraction	Michigan	11	↓	WISC-R Similitudes	Jacobson and Jacobson 1996

	Faroe Islands	7	–	WISC-R Similitudes	Grandjean et al. 2001

Visual–spatial functions

 Visuo-motor integration	Oswego	3	↓	MSCA Block Building	Stewart et al. 2003b

		4.5	–	MSCA Block Building	Stewart et al. 2003b

	Michigan	4	–	BTVMI	Jacobson et al. 1990

	Netherlands	9	–	Rey Complex Figure Test copy	Vreugdenhil et al. 2004a

	Faroe Islands	7	–	WISC Block Design	Grandjean et al. 2001

 Mental rotation	Michigan	11	–	Mental Rotation	Jacobson and Jacobson 2003

 Visual discrimination	Michigan	4	–	KMFF	Jacobson et al. 1992


Period	Experimental Station	Control Station

Male	Female	Total	Number of trains	Male	Female	Total	Number of trains

Pre	666	575	1,241	257	290	216	506	239

Intervention	1,115	1,164	2,279	247	243	216	459	246

Post	585	555	1,140	254	254	199	453	253


Characteristics	Values

Sex

Male	41 (41.4%)

Female	58 (58.6%)

Profession

Medical Staff	31 (31.3%)

Nursing Staff	68 68.7%)

Age

Years 20 – 29	59 (59.6%)

Years 30 – 39	37 (37.4%)

Years 40 – 49	2 (2.0%)


Technique	Detection capability (mutant DNA/total DNA) (%)

Sanger sequencing	>10

Pyrosequencing	10

Next-generation sequencing	>1

Real-time	1

ARMS	0.1

Digital droplet PCR, BEAMing, PAP, TAM-seq, Safe-SeqS, CAPP-seq, PARE	<0.01


	dry season	wet season

	n	g kg−1 DM	n	g kg−1 DM

greater kudu (Tragelaphus scriptus)	14	22	±6	20	26	±16

giraffe (Giraffa camelopardalis)	13	20	±6	18	24	±11

nyala (Tragelaphus angasi)	9	46	±12	6	30	±14

impala (Aepyceros melampus)	15	99	±28	20	147	±70

waterbuck (Kobus ellipsiprymnus)	5	117	±31	19	117	±32

sable antelope (Hippotragus niger)	8	59	±6	9	52	±10

roan antelope (Hippotragus equinus)	5	128	±10	7	95	±29

blue wildebeest (Connochaetes taurinus)	15	138	±11	19	132	±18

tsessebe (Damaliscus lunatus)	3	140	±28	16	131	±23

African buffalo (Synceros caffer)	15	146	±24	20	121	±20

black rhino (Diceros bicornis)	10	17	±6	—	—

African elephant (Loxodonta africana)	20	47	±7	20	59	±14

warthog (Phacochoerus aethiopicus)	6	100	±12	6	163	±57

plains zebra (Equus burchelli)	6	126	±19	6	126	±16

white rhino (Ceratotherium simum)	10	75	±13	—	—


Data set (training number, category)	 	MHW-KELM	Gauss-KELM	Poly-KELM	Original ELM	SCG-BP

Wine Quality (2000, 7)	Mean	54.59	49.69	52.14	45.79	<10

Std.	±0.35	±0.52	±0.28	±0.85

p value	1.00	1.04e − 06	7.82e − 03	3.27e − 09	0

Time	1.159	1.133	1.372	3.520	7.159


Author, Year	Country	Study Design	Sample Size	Exposure Assessment	Outcome	Confounding Factors	Potential for Bias	Effect Size	Quality Score

Preterm birth and Birth weight

Ando and Hattori, 1973 [10]	Japan	Case-control study	713	Objective assessment, aircraft noise, ECPNL (dB)	LBW (<2500 g)	Gender, maternal age, occupation, parity	High	Higher rate of LBW in noisy area above 75 dBA	8

Knipschild et al., 1981 [11]	Netherlands	Case-control study	1840	Objective assessment, aircraft noise, 3 subgroups Ldn < 65 dBA, Ldn 65–70 dBA, Ldn > 70 dBA	LBW	Gender, parental income	High	18% LBW in low noise exposed group, 24% LBW in high noise exposed group, 29% in noise exposed above 70 dBA Dose response relationship between aircraft noise and LBW	8

Schell, 1981 [12]	USA	Cross-sectional study	115	Objective assessment, aircraft noise, SEL = 75–100 dBA	Birth weight Gestational length	Maternal age, obstetric history, parental weight and height, education, smoking, family income	High	r = −0.04, p = 0.76 males r = −0.22, p = 0.014 females r = −0.18, p = 0.16 males r = −0.38, p = 0.008 females	11

Matsui et al., 2003 [13]	Japan	Survey	160,460 births	Objective assessment, aircraft noise, WECPNL (dB) Control group <75 dBA Exposed subgroups 75–80 dBA, 81–85 dBA, >85 dBA	LBW (<2500 g) Preterm birth (<37 weeks)	Gender, maternal age, socio-economic status, live birth order No adjustment for smoking	High	OR = 1.32 (95% CI 1.18–1.48), p = 0.0001 in the highest level of exposure compared to control group OR = 1.25 (95% CI 1.1–1.4), p = 0.0018 in the highest level of exposure compared to control group	10

Congenital malformations

Jones and Tauscher, 1978 [14]	USA	Ecological study	225146 births 2105 defects	Above vs. below >90 dBA	Birth defects	Information not provided	High	1185 vs. 737 per 100,000 births p < 0.02	8

Edmonds et al., 1979 [15]	USA	Survey	1745 birth defects	Objective assessment, aircraft noise, high noise level exposure above 65 dBA Ldn	17 categories of birth defects	Socioeconomic status, race	High	Non significant differences in rates of birth defects in exposed and non-exposed groups	10


Research site identifier	Site A	Site B	Site C	Site D

Telehealth deployment

Year of introduction	2007	2009	2006	2010

Equipment purchased (P) or leased (L)	P	P	L	P

No. of telehealth units available for usea	165	79	n/a	40

No. of telehealth units in useb	104	39	200	34

Referral routes into telehealth

Community matrons	✓	✓	✓	✓

Case managers	✓			✓

Specialist respiratory nurses	✓	✓	✓

Specialist heart failure nurses	✓	✓	✓

GPs	✓

Telehealth stakeholders

NHS community healthcare provider	✓		✓	✓

NHS hospital trust	✓			✓

Clinical commissioning group		✓	✓

Equipment manufacturer	✓	✓	✓	✓

Local authority	✓	✓	✓

Community interest company		✓	✓

Private company		✓	✓


Mutation	Gene	Mutation type	AA	References

m.3730T>Y	ND1	Point mutation	Y142H	[39,48]

m.3425T>Y	ND1	Point mutation	V40A	[39,48]

m.5212T>C	ND2	Point mutation	L248P	[39]

m.10844A>C	ND4	Point mutation	T29P	[39]

m.14510delA	ND6	Point mutation	-	[39]


Region ITS1	Region ITS2

Species	Controls	Species	Controls

Candida albicans	C7	Candida albicans	C7

Candida glabrata	C11SC	Cladosporium sp.	C11LF, C11SC

Cladosporium sp.	C12ERH,	Fusarium oxysporum	C3, C8, C10MD

Fungal sp.	C6	Malassezia restricta	C8, C12ERH

Fusarium oxysporum	C3, C4, C5, C8, C10MD	Penicillium crustosum	C11ERH

Malassezia globosa	C13MD	Phoma sp.	C13ERH

Malassezia restricta	C11SD, C12SC	Saccharomyces cerevisiae	C2

Penicillium crustosum	C11ERH	Uncultured eukaryote	C7

Phoma sp.	C13ERH	Uncultured fungus	C11SC

Rhodotorula mucilaginosa	C12SC	Uncultured malassezia	C11MD, C11SC, C12SC, C13LF

Uncultured fungus	C1, C10ERH, C11SC, C13LFC, C13MD	Pichia membranifaciens	C11MD

Uncultured malassezia	C11MD, C13SC

Uncultured rhodotorula	C11LF